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Vitamins are a group of biochemically and metabolically diverse essential micronutrients 
required for health, homeostasis, and development. The majority of vitamins cannot be 
endogenously synthesised sufficiently to satisfy physiological requirement, and therefore 
must be dietary sourced. Transit of vitamin metabolites through the circulation is 
facilitated by a number of transport proteins. Proteomic analyses have indicated three of 
these transport proteins; vitamin D-binding protein, haptocorrin (vitamin B12-binding 
protein), and retinol-binding protein (vitamin A-binding protein) are constituents of a 
number of exocrine secretions, including saliva. The aim of this study was to determine 
whether salivary vitamin-binding proteins have assimilatory functions in respect to their 
corresponding vitamin ligands, or if they support oral homeostasis.  
 
The relationships between salivary and serum vitamin-binding protein concentrations 
with commonly employed circulatory markers of systemic vitamin status were determined 
to assess their suitability as non-invasive biomarkers of vitamins status. Studies were 
undertaken to define the origin of vitamin-binding proteins in the oral cavity, which may 
relate to their function.  
 
Vitamin deficiencies have been reported in the common inflammatory disorder; 
periodontal disease. In this study, longitudinally paired saliva and serum samples from a 
periodontal disease cohort were assessed before and after treatment to determine if 
hypovitaminosis was a consequence of disrupted salivary vitamin-binding protein 
function. Interactions between haptocorrin, and the periodontal disease-associated 
pathobiont; Porphyromonas gingivalis, were experimentally considered. 
 
The findings of this thesis indicate the vitamin-binding proteins studied originated from 
salivary glands and their outputs increased with mastication. Upregulation of salivary 
flow (as would occur during the oral processing of food) demonstrated a greater output 
of salivary vitamin-binding proteins compared to resting flow, thus potentially exerting an 
assimilatory function. Vitamin-binding proteins were however, present in saliva at resting 
flow, suggesting they may contribute to the maintenance of oral homeostasis. Data 
presented in this thesis suggest the vitamin B12-binding protein; haptocorrin, exerted a 
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Chapter 1 Introduction 
1.1 Vitamin theory and classification 
1.1.1 A brief history of vitamins 
Vitamins are a biochemically diverse group of essential micronutrients required to 
support metabolic homeostasis. For the majority, vitamins cannot be synthesised de 
novo by humans; therefore, must be exogenously sourced. The term vitamin derives 
from vitamine or vital-amine which was coined in 1912 by Polish biochemist Casimir Funk 
who isolated a group of micronutrients found to be essential for life and assumed them 
to be amines, this was later found to be incorrect and subsequently the “e” was dropped 
(2). The field of nutrition research in the nineteenth century was centred around the 
opinion that the essential components of nutrition were: proteins, carbohydrates, fats, 
and minerals. Upon the advent of germ theory, numerous aetiological organisms for 
human diseases were being identified, this highlighted a number of prominent diseases 
such as: pellagra, rickets, beriberi, and scurvy; the causes of which remained elusive. 
Such diseases would later be attributed to nutritional deficits. The retrospectively named 
“vitamin theory” was presented in 1906 by British biochemist Frederick Gowland 
Hopkins, while working at Guy’s Hospital in London (3). He proposed that optimal health 
could not be sustained on the current dogma of nutritional research and suggested there 
were other key components of the diet which were required for life. The bulk of research 
into vitamins was undertaken between the early nineteenth to mid twentieth centuries.  
 
1.1.2 Vitamin classification 
Vitamins are typically classified by their solubility. With the lipid-soluble group comprising 
vitamins; A, D, E, and K; and the water-soluble group consisting of the B-complex 
(vitamins; B1, B2, B3, B5, B6, B7, B9, and B12); and vitamin C (4, 5). Although grouped by 
solubility; each vitamin is structurally distinct, and therefore the vitamins facilitate a 
diverse number of metabolic roles. Each vitamin title is typically used in reference to a 
group of structurally and metabolically homologous compounds. 
 
1.1.3 Defining vitamin assimilation 
Vitamin assimilation refers to the processes required to sustain the vitamin requirement 
of cells. Pathways typically involve oral and gastric processing of foods, absorption in 
the gastrointestinal tract, biochemical processing, which often occurs in the liver, and 




1.2 Vitamin D  
1.2.1 Metabolism and physiology 
Vitamin D is the collective name given to a family of steroids, the most physiologically 
important being vitamin D2 (ergocalciferol), and vitamin D3 (cholecalciferol) (Figure 1-1). 
Vitamin D is relatively sparse in the diet. Ergocalciferol is synthesised largely by fungi, 
from the UVB irradiation of ergosterol, though some data indicates this metabolite is less 
effective at improving vitamin status than cholecalciferol (6). Cholecalciferol is present in 
some animal products such as eggs, oily fish, and some meat products (7). Unlike the 
other vitamins, vitamin D3 can by dermally synthesised de novo by humans with 
ultraviolet-B (UVB) dependent conversion of 7-dehydrocholesterol to previtamin D3, 
which is then rapidly converted to cholecalciferol in a temperature-dependent reaction 
(8). The endogenous synthesis of vitamin D is dependent on a number of important 
factors, including exposure to the critical UVB wavelengths between 290-320nm, with 
the optimum range of 295-297nm (9, 10). Exposure to such wavelengths is highly 
dependent on geographical location with extremes of longitude, or seasonality greatly 
influencing vitamin D status (11, 12). The protective effect of dermal melanin against 
damage from solar radiation also reduces synthesis of vitamin D, therefore the degree 
of skin pigmentation can have implications for vitamin D status (13). Furthermore, the 
use of sun screens, and clothing choice can all impact endogenous synthesis of vitamin 
D (14).  
 
Vitamin D2/3 are biologically inert metabolites and must undertake two hydroxylation 
steps to become active, firstly 25-hydroxyvitamin D (25-OH-D) is generated in the liver 
by 25-hydroxylase, the second hydroxylation step occurs in renal tissue by 1-
hydroxylase and generates the hormonally active vitamin D metabolite; 1,25-
dihydroxyvitamin D (1,25-(OH)2-D) (calcitriol). Interestingly 1-hydroxylase activity has 
been identified in a number of extra-renal tissues including the gingival, suggesting 
Figure 1-1 Chemical structures of vitamin D metabolites 
(Left) ergocalciferol, (centre) cholecalciferol, (right) calcitriol 
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localised effects of vitamin D (15). The second hydroxylation of 25-OH-D to 1,25-(OH)2-
D is regulated by a negative feedback loop, responsive to circulatory concentrations of 
1,25-(OH)2-D. 25-OH-D has a significantly longer circulatory half-life than 1,25-(OH)2-D 
and consequently is a more stable indicator of vitamin D status (16). Currently there is 
no international consensus on optimal levels of vitamin D, though it is generally accepted 
that a serum concentration of 25-OH-D <50nmol/L is characteristic of deficiency (17).  
 
The physiologically active metabolite of vitamin D; 1,25-(OH)2-D, was initially identified 
as being an essential factor for mineral homeostasis. Acting on intestinal, renal, and 
skeletal tissues, vitamin D acts with parathyroid hormone (PTH) to regulate circulatory 
calcium and phosphorus concentrations (18). In the late 1960s, Haussler and Norman 
first described a nuclear receptor for which 1,25-dihydroxyvitamin D was the ligand, this 
discovery sparked a new interest in vitamins D, and indicated functions beyond the 
hormonal regulation of calcium (19). Expression of the vitamin D-receptor (VDR) has 
subsequently been identified in a large number of tissues including those of the digestive-
, respiratory-, and immune systems amongst others, and mechanisms describing the 
supportive role of vitamin D to physiology are numerous (20, 21).  
 
1.2.2 Assimilation 
Considering the variability of exposure to sufficient amounts of UVB radiation, for some 
populations around the globe, dietary vitamin D is particularly important (22). Being a 
group of lipid-soluble steroids, vitamin D is thought to follow the same absorption 
processes as lipids. Vitamin D is released from the food matrix with oral and gastric 
processing of food and incorporated into mixed micelles in the stomach and duodenum 
(23). Animal model studies indicate that at pharmacological doses vitamin D absorption 
occurs in a passive manner (24). However, more recent studies suggest that at dietary 
concentrations, vitamin D uptake is facilitated by a number of steroid receptors including 
scavenger receptor-class B type 1 (SR-BI), cluster determinant 36 (CD36), and 
Niemann-Pick C1-Like 1 (NPC1L1). These three receptors are expressed in the brush 
border membrane of the intestinal tract, and through the use of tissue culture and ex-
vivo animal experiments have been demonstrated to facilitate vitamin D uptake by 
enterocytes (25, 26). Vitamin D is incorporated into chylomicrons (lipoprotein particles 
consisting of triglycerides, phospholipids, cholesterol, and proteins) within the enterocyte 
and released into the lymphatic system by exocytosis, chylomicrons subsequently 
transfer to the circulation from which they are absorbed by the liver (27). In the circulation, 
the majority of 25-OH-D and 1,25-(OH)2-D is bound to the vitamin D-binding protein DBP, 
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and to a lesser extent albumin (28, 29). Binding of the lipid soluble vitamin D metabolites 
to DBP facilitates their transport in the aqueous phase of plasma. 
 
1.2.3 Vitamin D-binding protein 
Vitamin D-binding protein (DBP), also referred to as group-specific component (Gc-
globulin), is a multifunctional 58kDa globular glycoprotein which shares structural 
homology to the albumin protein family (30). DBP is capable of binding vitamin D and a 
range of metabolites including 25-OH-D and 1,25-(OH)2-D. Expression of circulatory 
DBP is predominantly undertaken by hepatic parenchymal tissue (31, 32). Vitamin D-
DBP complexes are taken up by cells in a receptor-mediated- endocytic process (33). In 
brief, complexes associate with low-density receptor-related protein 2 (LRP2/ megalin) 
and cubilin (CUBN) which facilitates uptake (34). Megalin and cubilin are responsible for 
the renal resorption of many complexes including Vitamin D-DBP which can be lost 
during the glomerular filtration of blood (33, 35, 36).  
 
It has been reported that as much as 98% of vitamin D-binding sites of circulatory DBP 
remain unoccupied with typical vitamin D status (37). This high degree of under-
saturation implies an alternative function to vitamin D transport. In addition to a vitamin 
D-binding domain, DBP is also able to bind G-actin monomers (38). Other functions of 
DBP include enhancing the chemotactic effect of the complement component 5a (C5a), 
which enriches infiltration of neutrophils and monocytes (39, 40). A number of studies 
have also shown that the sequential deglycosylation of DBP by -galactosidase and 
sialidase secreted from immune cells; generates a potent macrophage activating factor 
(MAF) which upregulates phagocytic activity (41). 
 
1.2.4 Epidemiology and manifestations of hypovitaminosis D 
Clinical assessment of vitamin D to categorise vitamin D status is typically based on 
circulatory 25-OH-D concentration. There remains a great deal of debate relating to what 
concentration constitutes a ‘healthy’ level (42, 43). Guidelines are typically based on the 
findings of large scale population analyses, which use bone mineral density and fracture 
rate as symptoms of insufficient concentrations which can lead to deficiency (43). 
Estimates suggest as much as 1 billion people globally are deficient in vitamin D ([25-
OH-D] <50nmol/L) with rickets and osteomalacia maintaining high prevalence around 
the world (44). Due to the number of factors which can influence endogenous synthesis 
of vitamin D, a large proportion of the global population are reliant on dietary or 
supplementary sources of vitamin D which can also vary greatly with the country of 
residence (45). A number of studies utilising data from the rolling National Diet and 
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Nutrition Survey (NDNS) which is undertaken annually in the United Kingdom, has 
highlighted certain fractions of the population are particularly at risk of deficiency. A 
prevalence of 25-OH-D (<25nmol/L) was observed in most age groups at 5-20%, and as 
high as 20-40% in young men and women over the age of 85. These values increased 
to as much as 75% for insufficient levels ([25-OH-D] <50nmol/L) (46-48). 
 
The first conditions to be associated with vitamin D deficiency were related to disrupted 
mineral homeostasis, and consequential skeletal disorders such as osteoporosis and 
osteomalacia in adults, and rickets in children (8, 49). Hypovitaminosis D has 
subsequently been associated with a large range of diseases, including autoimmune 
diseases such as multiple sclerosis, cardiovascular disease, dementia, and inflammatory 
diseases such as periodontal disease (50-53). There is growing evidence that 
supplementation with vitamin D, or sufficient UVB exposure can have a prophylactic 
effect on these conditions (54).  
 
1.2.5 Vitamin D and periodontal disease 
As with a number of other inflammatory diseases, low circulatory 25-OH-D concentration 
has been associated with periodontal disease, which is a chronic inflammation of the 
periodontium (tissues supporting the dentition), the inflammation leads to destruction of 
the these tissues (55, 56). Currently there is no clear consensus on the association in 
the literature which can largely be attributed to inter-cohort variation, and a lack of 
standardisation across studies (57). Mechanistically, the association may be 
multifaceted in cause, with vitamin D known to regulate bone homeostasis, via plasma 
calcium concentration, and VDR mediated bone resorption (58, 59). Furthermore, 
vitamin D has been demonstrated to attenuate inflammatory responses via the vitamin 
D receptor, for example by inhibiting lipopolysaccharide (LPS) induced activation of 
monocytes and macrophages, and subsequent cytokine release (60). Cathelicidin (LL-
37) is an important antimicrobial component of the innate immune system, inducing 
chemotaxis, increased vascular permeability, and is bactericidal by oligomerising in 
microbial membranes and disrupting their integrity (61). The expression of LL-37 is 
regulated by VDR, and is therefore regulated by the concentration of 1,25-(OH)2-D (62). 
Limited data suggests supplementation of 1,25-(OH)2-D in a periodontal disease mouse 
model reduces inflammation by upregulating LL-37 expression (63). 
 
In vitro studies have demonstrated vitamin D metabolites can be protective against 
inflammation in periodontal ligament cells and gingival fibroblasts by modulating cytokine 
concentrations (64, 65). Limited data also suggests 1,25-(OH)2-D may inhibit growth and 
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virulence of P. gingivalis, which is a keystone pathobiont species, strongly associated 
with periodontal disease, and reduce the severity of inflammation by inhibiting nuclear 
factor kappa B (NF-B) function (66). 1,25-(OH)2-D reduces NF-B activity by increasing 
expression of I kappa B alpha (IB-), which in turn reduces translocation of NF-B to 
the nucleus and therefore attenuates its function (67). 
 
Clinical supplementation studies in a cohorts of periodontal disease patients have 
demonstrated modest improvements to clinically quantifiable parameters of periodontal 
disease severity, and indeed improved health of the periodontium has been observed in 
patients on maintenance therapy (68-70).  
 
1.3 Vitamin B12  
1.3.1 Metabolism and physiology 
Vitamin B12 or cobalamins, denotes a group of water-soluble organometallic compounds 
which are synthesised de novo by a small group of prokaryotic and archaeal species in 
a hydroxylated form (71, 72). Humans must source vitamin B12 from foods of animal 
origin as no reliable plant source. Structurally, vitamin B12 consists of two invariable 
moieties, a corrin ring, and nucleotide loop, and interchangeable R-group (Figure 1-2) 
(73). Physiologically active R-groups in humans are adenosyl- or methyl-cobalamin, 
Figure 1-2 Chemical structure of vitamin B12 (cobalamin) 
The R group is interchangeable. Microbially synthesised as OH-cobalamin, pharmaceutically 





though cyano-cobalamin is a commonly produced pharmaceutical analogue which is 
stable and easily processed (74).  
 
Adenosylcobalamin (5’-deoxyadeadenosylcobalamin) is a cofactor for the mitochondrial 
protein methylmalonyl-CoA mutase, which catalyses the production of succinyl CoA from 
methylmalonyl CoA, an intermediary step in succinate biosynthesis (75). The 
cytoplasmic methionine synthase requires methylcobalamin as a cofactor, in the methyl-
tetrahydrofolate (methyl-THF) form of folate dependent synthesis of methionine (76). The 
two substrates for these enzymes, methylmalonic acid (MMA) and homocysteine (Hcy) 
are often utilised as functional biomarkers of vitamin B12 status (77). 
 
The aforementioned necessity of vitamin B12 for two key metabolic processes renders 
vitamin B12 essential for a number of fundamental cellular functions. As noted earlier, 
synthesis of the essential amino acid, methionine is vitamin B12 dependent, therefore 
protein synthesis and methylation are affected by hypovitaminosis B12. Secondly, 
donation of the methyl group from methyl-THF, allows THF to be converted to methylene-
THF which is an important intermediary in thymidylate synthesis, and ultimately DNA 
replication (76).  
 
1.3.2 Assimilation 
Vitamin B12 (cobalamin) is present in the diet in very low concentrations, although 
essential for life, its requirement is also low. A complex multi-step pathway (Figure 1-3) 
has evolved to assimilate a high proportion of dietary vitamin B12. Three homologous 
vitamin B12 binding proteins facilitate three distinct steps in uptake and transport. Firstly, 
haptocorrin (Hc) (please refer to 1.3.3), a salivary protein which is also expressed by the 
gastric mucosa is highly glycosylated and is thought to protect vitamin B12 from hydrolysis 
in the acidic environment of the stomach upon dissolution from food (78). The complex 
passes into the duodenum where the luminal pH gradient increases reducing the binding 
affinity of haptocorrin for the vitamin (79). Pancreatic proteases trypsin and pepsin cleave 
the binding protein releasing cobalamin (80). Hypovitaminosis B12 is observed in 30% 
of patients suffering pancreatic insufficiency (i.e. a failure to secrete the correct cocktail 
of proteases and buffering compounds), due to haptocorrin-cobalamin complexes 
remaining intact, which are not recognised by receptors expressed in the gastrointestinal 
tract (80-83). Liberated cobalamin in the proximal small intestine is bound by a second 
binding protein, termed intrinsic factor (IF) which is secreted by parietal cells located in 
the gastric mucosa, but fails to bind cobalamin at low pH, and therefore binding occurs 
in the duodenum where the pH is neutralised (80, 84). IF-cobalamin complexes are 
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absorbed across the brush boarder membrane (BBM) by interacting with the multiligand 
receptor cubilin (CUB) and amnionless (AMN), these two proteins form the cubam 
complex which facilitates endocytosis, and are expressed in the terminal ileum (85, 86). 
Within the enterocyte lysosome intrinsic factor is cleaved (87). Free cobalamin is 
transported into the circulation via the ABC transporter, multi-drug resistant protein 1 
(MRP1), expressed on the basolateral membrane (88). In plasma, cobalamin is bound 
by the third binding protein, transcobalamin-II (TCN-II) (89). Only the circulatory fraction 
of cobalamin bound to TCN-II is accessible, and is taken up by cells by the TCN-II 
receptor (TCN-II R) (90). 
 
1.3.3 Haptocorrin 
Haptocorrin (Hc), also referred to as transcobalamin-I (TCN-I) or R-binder is a 48KDa 
glycoprotein present in numerous exocrine secretions including saliva, tears, and milk 
Salivary haptocorrin (Hc) 
Cobalamin (Cbl) 
Gastric Haptocorrin 










Figure 1-3 Canonical cobalamin assimilation pathway 
1 - Cobalamin released from food proteins binds haptocorrin with a strong affinity at low pH. 2 - 
Extensive glycosylation of haptocorrin confers protection from hydrolysis in the gastric acidic 
milieu. 3 - Cobalamin is released in the duodenum with the increased pH and proteolytic 
degradation of haptocorrin. 4 - Cobalamin binds intrinsic factor, a homologous binding protein 
with greater specificity for physiologically active analogues, expressed by gastric parietal cells. 5 





and is also expressed by granulocytes (91, 92). Haptocorrin is distinct from the other two 
transport proteins (intrinsic factor and transcobalamin-2) in that it is able to bind 
physiologically inactive analogues of cobalamin as well as those required by humans 
(93, 94). Haptocorrin is also present in serum and binds the majority of circulatory vitamin 
B12; however, this fraction is only available to hepatocytes via the asialoglycoprotein 
receptor (95, 96). There is limited data in the literature which implies the potential 
antimicrobial function of haptocorrin, which is suggested to be a result of vitamin B12 
sequestration, for many bacteria cobalamins are exogenously sourced micronutrient and 
therefore a deficiency can be growth limiting (97-99). 
 
1.3.4 Epidemiology and manifestations of hypovitaminosis B12 
The predominant aetiology of vitamin B12 deficiency varies across the globe. For 
populations following vegetarian and especially vegan diets which have low cobalamin 
concentrations, dietary insufficiency is typically the most prevalent source of deficiency 
(100). In communities consuming diets rich in vitamin B12, malabsorption is generally the 
most frequently attributed cause. Malabsorption of vitamin B12 can occur for a number of 
reasons including, pancreatic insufficiency, a lack of intrinsic factor commonly as a result 
of parietal cell atrophy, or inflammatory disorders of the terminal ileum (101-103). Vitamin 
B12 deficiency in the United Kingdom is particularly prevalent in the elderly with 5% 64-
74-year olds being deficient, rising to 10% in the over 75s. Deficiency prevalence is even 
higher in the vegan population, to almost 50% (104, 105). 
 
Due to the fundamental importance of vitamin B12 to metabolic and cellular processes, 
deficiency can manifest in a number of ways. Typically, megaloblastic anaemia is an 
early indicator of deficiency which occurs due to disruption of DNA synthesis, 
desynchrony between nuclear and cytoplasmic maturation occurs and disrupts mitosis 
(106). If left untreated, vitamin B12 can cause other issues and can have serious 
neurological implications such as motor disturbances, memory loss and even psychosis, 
attributed in part to demyelination (106).  
 
1.3.5 Vitamin B12 and periodontal disease 
The literature supporting an association between vitamin B12 status and periodontal 
disease is small, with one study demonstrating an inverse association between markers 
of vitamin status (total-B12) and clinical indicators of periodontal disease progression 





1.4 Vitamin A  
1.4.1 Metabolism and physiology 
Vitamin A denotes a group of lipid-soluble compounds described as provitamin A, which 
comprises carotenoids of plant origin: -carotene, -carotene, and -cryptoxanthin, 
which are highly abundant in carrots and collard greens (108, 109). Preformed vitamin A 
refers to retinyl esters and retinol (Figure 1-4 (i)) which are sourced from animal dietary 
components such as cod liver and eggs (110). The functions of retinoids can broadly be 
grouped into the production of 11-cis-retinal (Figure 1-4 (ii)), which is required for vision, 
and the production of retinoic acid (RA) (Figure 1-4 (iii)), which is required for modulating 




The importance of vitamin A for vision has been well delineated. A chromophore vitamin 
A derivative, 11-cis-retinal, binds rhodopsin and cone opsins in photoreceptors. Photons 
induce the isomerisation of this derivative from cis- to trans- coordination which is critical 
for the transduction of sight (111). It is becoming increasingly apparent that vitamin A is 
essential for a number of other functions such as regulation of immunity, particularly at 
mucosal surfaces by modulating receptor expression such Toll-like receptor 2 and sIgA 
concentration (112), and cellular differentiation and morphogenesis (113). Vitamin A in 
Figure 1-4 Chemical structure of vitamin A metabolites 






the forms all-trans-retinoic acid, and 9-cis-retinoic acid, are the ligands for the nuclear 
receptors; retinoic acid receptor (RAR), and retinoid X receptor (RXR), which bind to the 
widely-occurring retinoic acid response elements (RAREs) and subsequently regulate 
gene expression (114, 115).  
 
1.4.2 Assimilation 
Vitamin A and the other lipid soluble vitamins are considered to emulsify into mixed 
micelles as they dissolute from the food matrix and separate into the lipid fraction of the 
meal. Studies have shown that vitamin A is incorporated into chylomicron and micelles, 
with very little processing in the stomach, excluding hydrolysis of retinyl-esters (116). 
Previous research undertaken by Hollendar et al. in the 1970s presented data suggesting 
carrier-protein mediated passive diffusion is responsible for gastrointestinal uptake of 
vitamin A analogues; however, these studies undertaken on ex vivo rat intestines, were 
using pharmaceutical concentrations (117, 118). More recent work has focused on 
physiological concentrations of vitamin A, and transit across enterocytes via receptor 
mediated pathways (119). The steroid receptors described in the assimilation of vitamin 
D (SR-B1, CD36, and NCP1L1) are also implicated in receptor mediated uptake of 
vitamin A from the gastrointestinal lumen (119). Animal models have been a useful tool 
in deciphering the site of gastrointestinal absorption. Uptake is detectible in the small 
intestine and is minimally so in the caecum and colon (120). Vitamin A circulates 
predominantly bound to retinol-binding protein RBP (121). Cellular uptake of the RBP-
retinol complex is facilitated by “stimulated by retinoic acid-6” (STRA6), a widely 
expressed, specific transmembrane transporter (122, 123). 
 
1.4.3 Retinol-binding protein 
Retinol-binding protein (RBP/ RBP4) is a 21kDa plasma protein, expressed 
predominantly by hepatocytes, and to a lesser extent in more distal tissues such as renal 
parenchyma and adipose (124, 125). RBP circulates bound to another hepatically 
expressed 55kDa protein; transthyretin, which increases the molecular weight of the 
complex and therefore reduces loss during glomerular filtration (126). Recent 
developments suggest RBP may function as an adipokine and be an indicator of insulin 
resistance in type 2 diabetes though this remains contentious in the literature (127). 
 
1.4.4 Epidemiology and manifestations of hypovitaminosis A 
Hypovitaminosis A remains a major global health problem with an estimated prevalence 
of 130 million children, and 7 million pregnant women in lower-income countries, and is 
predominantly attributed to dietary insufficiency, and to a lesser extent malabsorption 
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(128). Extremes of vitamin A status hypo-/hyper-vitaminoses A, has been attributed to 
increased mortality in the elderly (129). The supportive function of vitamin A to immunity 
means that deficiency is associated to a high rate of child mortality from infectious 
diseases, particularly diarrheal attributed mortality (130). 
 
Vitamin A deficiency can manifest is a variety of ways, most acutely as night-blindness, 
which is a reduced ability to adapt to reduced light intensity, this is the most common 
symptom of xerophthalmia (131). Xerophthalmia is a collection of ocular conditions 
associated with hypovitaminosis A, including dryness, and inflammation (132). Vitamin 
A deficiency is associated with infections and reduced mucosal barrier function (133, 
134).  
 
1.4.5 Vitamin A and periodontal disease 
There is increasing evidence that oxidative stress (OS) can have negative health 
implications for the oral cavity, including periodontal tissues (135, 136). Sources of OS 
in the oral cavity are numerous and include, food, inflammation and smoking (136). 
Nutritional studies have indicated that, dietary or supplemented antioxidants, such as 
pro-vitamin A carotenoids, -tocopherol (vitamin E), and vitamin C can increase the rate 
of healing in periodontal tissue when assessed by pocket depth in non-smoking 
periodontal disease patients (137). 
 
1.5 Saliva and vitamin-binding proteins 
Whole mouth saliva (WMS) is the complex product of three pairs of major salivary glands, 
numerous minor glands, as well as contaminants from the gingival crevicular fluid, the 
oral epithelia, microbiome and consumed items (138). Typical resting whole mouth saliva 
secretion is 0.3-0.4mL/minute although there is great range (139). Saliva contributes to 
the efficient functioning of the oral cavity, and upper digestive tract. Members of the 
complex salivary proteome include the aforementioned three vitamin-binding proteins; 
vitamin D-binding protein (DBP), haptocorrin (Hc), and retinol-binding protein (RBP) 





1.5.1 Anatomy of the major salivary glands 
Whole mouth saliva is the product, in part, of the major salivary glands which are 
bilaterally paired exocrine glands consisting of the parotid, sublingual, and 
submandibular glands (1). Ducts channel the saliva into the oral cavity onto the oral 
mucosa (Figure 1-5).  
Salivary gland parenchyma is composed of two distinct epithelial tissues. Firstly, the 
acinar epithelium, responsible for secreting salivary fluid, as well as the majority of the 
salivary proteome, and secondly, the ductal epithelium which modify salivary ionic 
content as well as contributing some proteins as saliva is channelled into the oral cavity 
(142). Parenchymal tissue is arranged into lobes separated by connective tissue which 
is densely populated by nerve fibres, vasculature, and myoepithelial cells (143). 
 
The microstructure differs between the major glands and consequently influence the 
composition properties of their secretions (144). One key variance between the glands 
is the composition of acinar cell types within the parenchyma, defined by the secretory 
proteins they synthesis. Secretions from the various glands are typically divided into 
mucinous or non-mucinous (Figure 1-6). Histological staining of the major glands with 
haematoxylin and eosin demonstrates the parotid gland acinar cells are predominantly 
serous (non-mucinous) and sublingual being largely mucinous, the submandibular 







Duct of Rivinus 
Figure 1-5 Anatomy of the left side major salivary glands and corresponding 




The parotid and submandibular glands contain intercalated, striated, and excretory 
ducts, the sublingual gland however, lacks striated ducts. Striated ductal cells have the 
machinery required for ion resorption which is responsible for the hypotonicity of these 
secretions (145). 
 
1.5.2 Saliva secretion 
Saliva secretion by the major glands is stimulated by chemoreceptors and other taste 
receptors, located within taste buds, primarily distributed in the dorsal epithelium of the 
tongue, and by mechanoreceptors within the periodontal ligaments and mucosa (146, 
147). The salivary reflex has been well delineated, in brief, afferent signals from the 
aforementioned receptors in the oral cavity are transmitted to the trigeminal nucleus, and 
nucleus solitary tract, which in turn transmit signals to the salivary nuclei. Efferent signals 
are subsequently transmitted via the glossopharyngeal, and lingual nerve, to the parotid, 
and sublingual/ submandibular glands respectively (1). Innervation of the salivary glands 
is controlled by both sympathetic and parasympathetic branches of the autonomic 
Myoepithelial cells 
Serous acinus 





Figure 1-6 Architecture of a generalised salivary gland 
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nervous system. Parasympathetic innervation of the glands is mediated by acetylcholine 
activation of muscarinic receptors leading to ion and water secretion. Sympathetic 
release of noradrenaline activates 1-adrenergic receptors, stimulating protein secretion 
(148). (Acinar secretion of saliva is summarised in Figure 1-7). Salivary flow rate and 
composition can vary under circadian control and the type of stimulant; therefore, it can 













































Figure 1-7 Simplified cellular processes of acinar saliva secretion 
Acinar Ion and water secretion 
Fluid secretion is driven by parasympathetic stimulation of muscarinic receptors. Polarisation of 
acinar cells features distinct localisation of different ion on water receptors to facilitate the 
direction of secretion into the glandular lumen. The ATP dependent sodium pump in the 
basolateral membrane of acinar cells maintains a low intracellular sodium concentration, 
inducing the movement of chloride and sodium ions through the cell into the acinus lumen which 
creates an osmotic gradient. This induces water to follow either intercellularly or intracellularly 
via aquaporin 5 (Ag5), thus creating the fluid component of saliva.  
Acinar protein secretion 
Protein secretion is driven by sympathetic stimulation of 1-adrenergic receptor activation which 
in-turn increases the cytosolic cAMP concentration, and activation of protein kinase A (PKA), 
subsequently exocytosis is induced.(1)  
AdC Adenylate cyclase IP3 Inositol triphosphate 
Aq5 Aquaporin 5 IP3R Inositol triphosphate receptor 
ATP Adenosine triphosphate  K
+ Potassium 
Ca2+ Calcium ion Na
+ Sodium ion 
cAMP Cyclic AMP NKCC1 Sodium, potassium, chloride co-transporter  
Cl- Chloride ion PIP2 Phosphatidyl inositol bisphosphate  
Gq G protein q PKA Protein kinase A 
Gs G protein s PLC Phospholipase C 





1.5.3 Sources of the whole mouth salivary proteome 
The majority of salivary proteins are expressed by the salivary glands, though there is 
great inter-glandular variation in which proteins are synthesised (144). As illustrated by 
Figure 1-7, proteins expressed by acinar cells are packaged densely into secretory 
granules with the aid of calcium ions to balance charge, proteins are released by 
exocytosis upon autonomic innervation of the glands (see number 3, Figure 1-8) (149, 
150). Saliva contains proteins from blood, interstitial, and plasma cell proteins (such as 
sIgA) which can enter the end piece lumen either paracellularly (see number 1, Figure 
1-8), or transcellularly (see number 2, Figure 1-8) (151, 152). Whole mouth saliva further 
contains proteins from shed oral epithelial cells, the transudate gingival crevicular fluid, 
and from the oral microbiota. 
 
1.5.4 Saliva composition and functions 
Saliva is biofluid composed of ions and a complex proteome of 2000 proteins (152). 
The diversity of salivary constituents facilitates the numerous functions of saliva in 
maintaining the roles of the oral cavity. Although saliva is 99% water, its constituents 
render it a non-Newtonian fluid (i.e. it demonstrates reduced viscosity with increased 
shear forces). Shear forces are common in the oral cavity, for example during chewing, 
and this property facilitates lubrication for the mechanical functions in the mouth (153, 
154). The non-Newtonian attributes of saliva are in part attributable to the large molecular 
weight glycoproteins; mucins (155). Mucins also add to the adhesive quality of saliva (the 
Glandular saliva 






Figure 1-8 Glandular sources of salivary proteins.  





extensional rheological property termed spinnbarkeit), this facilitates the ability of saliva 
to coat the oral surfaces (156). By coating the structures of the mouth, saliva is able to 
facilitate many other functions. Saliva is a medium which enables the dissolution of 
tastants from the food matrix and detection by receptors expressed in the oral mucosa 
(157, 158). Saliva has further been shown to be essential for detection of the basic taste 
modalities (i.e. sweet, sour, bitter, umami, and salt) as well as more complex perceptions 
such as astringency (159). The physical properties of saliva are also essential for 
effective swallowing of food, in addition to its lubricating ability, the adhesive nature of 
saliva allows the aggregation of the food particles produced during mastication, to form 
a bolus prior to swallowing (160). 
 
Further to the gustatory functions of saliva, it is critical for homeostasis of the oral cavity. 
Adsorption of salivary proteins onto both the oral hard and soft tissues offers a protective 
layer termed the pellicle (mucosal and enamel) resisting abrasion, erosion and facilitating 
microbial adhesion (161-163). Numerous antimicrobial components are present in saliva 
which demonstrate anti-bacteria (alpha-defensins), anti-viral (cystatins), and anti-fungal 
(cathelicidin) properties (164). Components such the growth factors; EGF and VEGF are 
also present and aid repair of oral tissues (165). 
 
1.6 Periodontal disease and the pathobiont Porphyromonas 
gingivalis 
As noted in sections 1.2.5, 1.3.5, 1.4.5, some literature demonstrates associations 
between systemic micronutrient status and periodontal disease. Periodontal disease is 
a collection of inflammatory disorders affecting the supportive tissues of the dentition. A 
milder form of gum inflammation is gingivitis which involves inflammation of the soft 
tissues around the teeth (gingiva) in response to the adjacent biofilm (plaque) which 
develops in the gingival sulcus. Gingivitis can usually be rectified with more thorough 
oral hygiene. If left untreated, gingivitis can develop into periodontitis (166). Periodontitis 
is a destructive inflammatory condition of both hard and soft tissues supporting the teeth, 
which can lead to attachment loss of the periodontal ligament to the dentition and 
resorption of the alveolar bone, eventually resulting in tooth-loss. The classification 
system of periodontal disease was recently redefined (2017) and now considers the 
aetiology when classifying the disease (167, 168). The aetiology of periodontal 
inflammation is considered to be a disruption of host homeostasis by dysbiosis in the 
subgingival plaque, this is followed by an overzealous immune response leading to tissue 




1.6.1 Epidemiology of periodontal disease 
Periodontal disease is one of the two most prolific inflammatory diseases worldwide and 
a significant contributor to chronic disease globally (170). The global prevalence of 
periodontal disease is 10-15% in adults (171). Susceptibility to periodontal disease is 
known to be related to a number of genetic factors as well as environmental such as 
nutrition, oral hygiene, smoking status, and systemic diseases the most notable of which 
being diabetes (172, 173).  
 
1.6.2 Commensal oral microbiota  
Colonisation of the oral cavity by complex communities of microbes including, bacteria, 
viruses, fungi, and archaea is a natural feature of healthy oral homeostasis (174). 
Typically, the commensal species support the healthy environment of the oral cavity by 
outcompeting, or even inhibiting proliferation of more pathogenic species (175). 
Interestingly the oral microbiota has recently been demonstrated to have implications for 
systemic hypertension. Nitrate in saliva is a substrate for certain bacteria and is reduced 
to nitrite, which in turn is a precursor of anti-hypertensive nitric oxide which regulates 
endothelial function in the vasculature (176, 177).  
 
Adsorbed salivary proteins on oral surfaces offer a natural barrier to limit direct contact 
between microbes and the oral mucosa, and frequent swallowing limits microbial 
biomass accumulation (178). Discrete environmental niches in the oral cavity leads to 
site specific microbial ecology (179). Niches within the oral cavity include the gingival 
sulcus, the enamel surface, the tongue, the hard and soft pallets, and oral prostheses 
(180).  
 
1.6.3 Microbial dysbiosis 
During the transition into a periodontal disease state, the subgingival plaque composition 
shifts from a diverse community of predominantly Gram-positive species to a more 
restricted community of Gram-negative anaerobes (181). Analysis of plaque has 
indicated close association of microbial species including Porphyromonas gingivalis, 
Tannerella forsythia, and Treponema denticola and an enrichment of their virulence 
factors at sites of inflammation (182, 183). This cohort of species is termed the “red 
complex” (184). Of the red complex, Porphyromonas gingivalis is considered the 
“keystone species”, although present in low amounts, even in a disease state, its 
virulence factors can direct the dysbiosis of the subgingival microbiota which is a key 




1.6.4 Porphyromonas gingivalis and its cysteine proteases 
Porphyromonas gingivalis (P. gingivalis) is Gram-negative anaerobic bacterial species 
with a strong association to periodontal disease (186). Meta-analysis has indicated P. 
gingivalis is present in 78% of periodontal disease patients, compared to just 34% of 
periodontally healthy controls (187). P. gingivalis possesses an arsenal of key virulence 
factors which allow it to act as a keystone species and modulate not only plaque 
composition, but also host immune response (188). One of the key virulence factors of 
P. gingivalis is a group of promiscuous cysteine proteases termed “gingipains” (189). 
Gingipains are both secreted, or membrane associated, and consist of two arginine-
specific proteases RpgA/B, and a lysine-specific protease Kgp (189). Expression of 
gingipains is regulated in response to environmental factors, such as nutrient availability, 
for example haemin concentration (190, 191). Significant literature demonstrates the 
contribution of gingipains to subversion of immunity, tissue infiltration, and nutrient 
requisition. Arg-X gingipains in particular, have been shown to first stimulate a localised 
immune response, therefore providing essential nutrients, at high enough concentrations 
gingipains cleave chemotactic compliment components C3 and C5, thus reducing 
neutrophil recruitment (192, 193). Gingipains are essential for a number of nutrient 
sourcing processes, one important process is in liberating haemin from erythrocytes 
(194). Searching for novel virulence factors which support P. gingivalis fitness continues 
to be a focus in the literature with the generation of transposon mutant libraries, which 
can be a high throughput method for highlighting essential genes (195).  
 
1.6.5 Porphyromonas gingivalis and the cobalamin biosynthesis pathway 
As noted in chapter 1.3, the cobalamin biosynthesis pathway is a complex ~30 enzyme-
dependent process conserved in a small number of microbial species. The pathway has 
been delineated and demonstrates at least two distinct routes either aerobic or anaerobic 
(196). Extracts of various P. gingivalis strains has demonstrated a lack of activity for two 
essential enzymes in the anaerobic pathway, and this is supported by genomic analysis. 
It is proposed the remainder of the pathway is conserved as a scavenging pathway for 
conversion of inactive analogues (197). There is no literature which assesses the 




1.7 Thesis aims and objectives 
Although researched in detail in the circulation, the functions of vitamin D-binding protein, 
haptocorrin, and retinol-binding protein, in the context of saliva, have been minimally 
described in the literature. The overall aim of this thesis is to determine if vitamin-binding 
proteins present in saliva contribute to dietary vitamin assimilation, and to understand 
the influence they have on microbial growth. To achieve this, the following objectives will 
determine how well salivary and serum concentrations correlate in healthy controls, 
whether vitamin-binding proteins change during inflammation, and if they inhibit growth 
of bacteria.  
 
1.7.1 Objectives 
The key objectives of this thesis are: 
 
1. To understand the relationship between salivary and serum vitamin-
binding protein concentrations with systemic vitamin status  
Saliva has great potential to be a non-invasive source of biomarkers which can 
be readily collected. Understanding the relationship between salivary vitamin-
binding proteins and systemic markers of vitamin status may offer salivary marker 
of vitamin status. 
2. To determine the contribution of different salivary glands to whole mouth 
salivary concentrations, and the influence of stimulation on their 
concentrations 
The concentrations of vitamin-binding proteins between resting and stimulated 
salivary flow may be suggestive of their function within the oral cavity, increased 
output with stimulation may be important for aiding dietary vitamin absorption. 
3. To understand the influence of periodontal disease on salivary vitamin-
binding protein concentration, and systemic vitamin status 
Periodontal disease is associated with a number of micronutrient deficiencies, is 
this a consequence of disrupted salivary vitamin-binding protein function? 
4. To understand the interactions between haptocorrin, and the keystone 
perio-pathobiont: Porphyromonas gingivalis 
Vitamin B12 is a nutritional requirement for a number of microbial species 
including a key aetiological species for periodontal disease. P. gingivalis lacks 
the complete anaerobic cobalamin biosynthesis pathway and therefore must 
source it exogenously. Haptocorrin, may therefore exert an innate immune 




Chapter 2 Common materials and methods 
This section describes the materials and methods common across multiple results 
chapters. Chapter specific methods will be covered within each chapter. 
 
2.1 Protein biochemistry methods 
2.1.1 Quantification of total protein by bicinchoninic acid assay 
Total protein concentration of all sample types was determined by bicinchoninic acid 
assay (BCA) (ThermoScientific, Waltham, MA, U.S.A). Equal volume of samples was 
added to a 96-well plate in duplicate. Albumin standard (2mg/mL) was serially diluted to 
generate an appropriate series. Fresh working reagent was then prepared and added to 
all wells. The plate was sealed and incubated for thirty minutes at 37C, absorbance was 
measured immediately after at 540nm using iEMS 96 well microplate reader 
(ThermoFisher, Waltham, MA, U.S.A.). Absorbance of the albumin titration was used to 
generate a standard curve from which the protein content of samples was generated. 
 
2.1.2 Western blot 
Samples were prepared in NuPAGE lithium dodecyl sulphate sample buffer 
(ThermoFisher, Waltham, MA, U.S.A.) and reduced with 1,4-Dithiothreitol (DTT) prior to 
heating to 100C for two minutes. The protein profile of saliva and molecular weight 
standard, SeeBlue Plus2 (ThermoFisher, Waltham, MA, U.S.A.) was separated using 
XCell Sure Lock Mini-Cell electrophoresis system on NuPAGE 4-12% Bis-Tris gels 
(ThermoFisher, Waltham, MA, U.S.A.), for thirty minutes at a constant of 200v.  
 
Proteins were transferred onto supported nitrocellulose membrane (Bio Rad, Hercules, 
CA, U.S.A.) over an hour at a constant of 30v. 
 
2.1.3 Immunoprobing 
Blots were blocked with 5% w/v skimmed milk powder (Sigma-Aldrich, St. Louis, MI, 
U.S.A) suspended in tris buffered saline with 0.1% tween20 (TBST) for one hour at room 
temperature with gentle agitation. Blots were incubated for one hour at room temperature 
with the following antibodies diluted in blocking agent. 
 
 
Target immunogen Clonality Host Working concentration Manufacturer 
Haptocorrin  Monoclonal Mouse 0.25µg/mL Novus Biologicals, Abingdon, U.K. 
Vitamin D-binding protein Polyclonal Rabbit 0.30µg/mL Abcam, Cambridge, U.K. 
Retinol-binding protein Monoclonal Rabbit 0.23µg/mL Abcam, Cambridge, U.K. 




Blots were then washed three times for five minutes at room temperature in TBST. 




Blots were again washed three times for five minutes at room temperature with TBST. 
Bands were visualised by chemiluminescence using ChemiDoc XRS+ (Bio-Rad 
Laboratories, Hercules, CA, U.S.A.) with enhanced chemiluminescence substrate (ECL) 
(Bio-Rad Laboratories, Hercules, CA, U.S.A.) in order to detect horseradish peroxidase 
(HRP) activity which is the reporter system conjugated to the secondary antibodies. 
Equal volumes of ECL system were mixed and applied to the membrane for 20 seconds, 
excess substrate was removed. Sequential imaging tool place to produce clear images 
prior to over exposure. Image Lab software (Version 4.0 build 16) (Bio-Rad Laboratories, 
Hercules, CA, U.S.A.) was used for analysis. 
  
2.1.4 Quantification of haptocorrin by ELISA 
Haptocorrin was quantified by sandwich enzyme-linked immunosorbent assay (ELISA). 
All reagents were provided in kit form (Cusabio biotech Co Ltd, Houston, TX, U.S.A.). 
Neat saliva and serum samples were assayed in duplicate on a 96-well plate precoated 
with monoclonal anti-haptocorrin antibody along with a titration of standard. Wells were 
aspirated and washed thoroughly five times with wash buffer. Another monoclonal anti-
haptocorrin biotinylated antibody was added to all wells and incubated at room 
temperature for thirty minutes. Wells were aspirated and washed thoroughly five times 
with wash buffer. Avidin-HRP conjugate was then added to each well and incubated for 
a further thirty minutes. Wells were aspirated and washed thoroughly five times with 
wash buffer. Two substrate solutions (stabilised hydrogen peroxide followed by 
tetramethylbenzidine) were added in sequence and incubated for ten minutes at 37C 
while restricted from light. Stop solution (6N sulphuric acid) was added and optical 
density values were measured at 450nm with an iEMS 96 well microplate reader 
(ThermoFisher, Waltham, MA, U.S.A.). The mean of duplicate standard and sample 
values were calculated, and the blank was subtracted from all values. Optical density 
 
Table 2-2 Secondary antibodies used for immunoblotting 
Target immunogen Conjugate Host Working concentration Manufacturer 
Mouse Ig HRP Goat 0.50µg/mL Dako, Santa Clara, CA, U.S.A. 
Rabbit Ig HRP Swine 0.65µg/mL Dako, Santa Clara, CA, U.S.A. 
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readings were plotted against corresponding concentrations on a scatterplot, a line of 
best fit was applied. The trend line equation was rearranged in order to calculate 
individual sample concentrations. 
 
2.1.5 Quantification of vitamin D-binding protein by ELISA 
Vitamin D-binding protein was quantified by sandwich enzyme-linked immunosorbent 
assay (ELISA). All reagents were provided in kit form (R&D Systems, Inc. Minneapolis, 
MN, U.S.A.). Saliva and serum samples were diluted two-fold, and two thousand-fold 
respectively in calibrator diluent, and loaded in duplicate onto a 96-well plate precoated 
with a monoclonal anti-DBP antibody, along with the provided standards, and incubated 
for two hours at room temperature with horizontal orbital rotation of 450rpm using iEMS 
96 well microplate reader (ThermoFisher, Waltham, MA, U.S.A.). Wells were then 
aspirated and thoroughly washed four times with wash buffer. Anti-DBP monoclonal 
antibody HRP-conjugate was then added to each well and incubated for one hour, again 
with horizontal orbital rotation at room temperature. Wells were again aspirated and 
washed four times. Substrate solution (1:1 ratio of stabilised hydrogen peroxide and 
tetramethylbenzidine) was then added for thirty minutes and incubated at room 
temperature without agitation and excluded from light. Stop solution (2N sulphuric acid) 
was then added, optical density was determined with iEMS 96 well microplate reader 
(ThermoFisher, Waltham, MA, U.S.A.) at wavelength 450nm, readings were also taken 
at 540nm and subtracted from the former to adjust for optical imperfections on the plate. 
The mean of duplicate standard and sample values were calculated, and the blank was 
subtracted from all values. Optical density readings were plotted against corresponding 
concentrations on a scatterplot, a line of best fit was applied. The trend line equation was 
rearranged in order to calculate individual sample concentrations. 
 
2.1.6 Quantification of retinol-binding protein by ELISA 
Retinol binding protein was quantified by sandwich enzyme-linked immunosorbent assay 
(ELISA) all reagents were provided in kit form (Invitrogen, Frederick, MD, U.S.A). Saliva 
and serum samples were diluted two-fold and one hundred-fold respectively in sample 
diluent. Samples and standards were added to the precoated monoclonal anti-RBP 
antibody assay plate biotin-conjugated monoclonal anti-RBP antibody was then added 
and incubated for two hours at room temperature with orbital agitation (400rpm). Wells 
were aspirated and washed four times thoroughly with wish wash solution. Streptavidin-
HRP conjugate was then added to all wells and the plate was incubated at room 
temperature with orbital agitation (400rpm) for one hour. Wells were then aspirated, and 
washing was repeated a further four times with wash buffer. Detector solution 
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(tetramethylbenzidine) was added to each well and incubated for thirty minutes at room 
temperature, excluded from light. Stop solution (1M phosphoric acid) was added to each 
well and optical density was measured at 450nm with an iEMS 96 well microplate reader 
(ThermoFisher, Waltham, MA, U.S.A.). The mean of duplicate standard and sample 
values were calculated, and the blank was subtracted from all values. Optical density 
readings were plotted against corresponding concentrations on a scatterplot, a line of 
best fit was applied. The trend line equation was rearranged in order to calculate 
individual sample concentrations. 
 
2.2 Vitamin quantification 
2.2.1 Determination of systemic Vitamin B12 and D status 
Total-vitamin B12, and 25-hydroxyvitamin D were quantified in serum samples as markers 
of systemic vitamin B12 and vitamin D status respectively. Quantification was undertaken 
by chemiluminescent microparticle immunoassay (CMIA) on an ARCHITECT i system 
(Abbott Diagnostics, Maidenhead, U.K.) at the Viapath Nutristasis Unit (St. Thomas’ 
Hospital, London). This is an automated high-throughput system used clinically. Daily 
calibration and controls are undertaken on the machine with known concentrations of 
each analyte to generate a standard curve. 200µL of sample are applied to sample cups 
(Abbott Diagnostics, Maidenhead, U.K.). Paramagnetic microparticles coated with 
monoclonal antibodies for the two metabolites are added to samples by automation. Post 
incubation, analytes bound to the microparticles are precipitated by magnetism and 
excess sample is aspirated, the microparticles are washed with buffer and resuspended 
in sample buffer which contains acridinium-labelled monoclonal antibodies targeted to 
the analyte. The precipitation and was steps are repeated, before hydrogen peroxide is 
added to each sample cub which induces the production of chemiluminescence which is 
measured as relative light units (RLUs). RLUs has a direct relationship to the analyte 
tested. 
 
2.2.2 Determination of systemic Vitamin A status 
Retinoic acid was quantified in serum samples as markers of systemic vitamin A status. 
Quantification was undertaken by high-performance liquid chromatography (HPLC) at 
the Viapath Nutristasis Unit (St. Thomas’ Hospital, London). The following set up was 
used: Dionex Ultimate 3000 pump and autosampler (ThermoFisher, Waltham, MA, 
U.S.A.) coupled with UV detector at 975nm (Jasco, great Dunmow, U.K.) BetaSil C18 




2.3 Statistical analysis 
All statistical analysis, and plot generation was undertaken using Prism 7 for Mac OS X 
Version 7.0a April 2, 2016 (GraphPad Software, Dan Diego, CA, U.S.A.). Specific 




Chapter 3 Salivary and circulatory vitamin-binding proteins in 
relation to vitamin status 
 
3.1 Rationale 
Saliva is often hailed as an attractive source of novel biomarkers for systemic disease, 
due to its non-invasive accessibility and diverse proteome which shares 25-30% 
homology to serum (198). Proteomic analysis of human saliva samples detected the 
presence of vitamin D-binding protein, haptocorrin, and retinol-binding protein (141). The 
three vitamin-binding proteins identified in saliva are also abundantly present in the 
circulation and have been studied in greater detail in that regard.  
 
Vitamin D is highly hydrophobic, therefore the binding of vitamin D metabolites by vitamin 
D-binding protein (DBP) improves solubility and aids transit through the circulation (29). 
DBP has been detected in a number of biofluids in addition to serum including whole 
mouth saliva, and gingival crevicular fluid (199). DBP is the major circulatory transporter 
of vitamin D metabolites with ~85% of 25-OH-D and 1,25-(OH)2-D complex to the protein 
(200). With such a large fraction of circulatory vitamin D metabolites being bound to DBP 
in the circulation, a number of studies have identified correlations between circulatory 
DBP concentrations and vitamin D status (200, 201). 
 
Haptocorrin is also present in the circulation where it binds ~80% of the vitamin B12 
present (91). The fraction of vitamin B12 bound to haptocorrin in the circulation is 
inaccessible to cells with no cellular receptor recognising the complex (79). Unique to 
vitamin B12-binding proteins, haptocorrin binds physiologically inactive analogues of the 
vitamin (94). It is proposed that haptocorrin may act as a filter to remove non-
physiologically active vitamin B12 analogues from the circulation via the 
asialoglycoprotein receptor (a lectin receptor expressed by hepatocytes which removes 
target glycoproteins from the circulation) (202). The circulatory concentration of 
haptocorrin is responsive to vitamin B12 status with low concentrations observed in 
patients with B12 deficiency and increasing in response to B12 supplementation (203). 
 
As with vitamin D, vitamin A metabolites are hydrophobic (121). Solubility is improved by 
complexing with retinol-binding protein (RBP), which also binds transthyretin to increase 
the molecular weight of the complex, thus preventing loss during glomerular filtration of 
blood (204). A number of published studies have shown strong correlations between 




Due to the strong relationships detected between circulatory DBP, Hc, and RBP with 
their corresponding vitamin ligands the aim of this study was to determine the 
relationship between vitamin-binding protein concentrations in both saliva, and serum, 
with systemic markers of vitamin status. The benefits of saliva over serum as a source 
of biomarkers indicate that similar correlations with salivary concentrations of the 
proteins would be clinically beneficial. A further aim of this study was to understand the 
relationship between the proteins and vitamins between the two fluids which may 
suggest a role for the binding proteins in dietary vitamin assimilation. 
 
3.2 Method 
3.2.1 Ethical approval 
Ethical approval for this study was obtained from the Biomedical Sciences, Medicine, 
Dentistry and Natural and Mathematical Sciences subcommittee of the King’s College 
London Research Ethics Committee (Reference: BDM/14/15-61).  
 
3.2.2 Participant recruitment and informed consent 
14 participants were recruited from within the university, via the research recruitment 
email system. An individual’s compatibility for the study was dependent on the following 
criteria; 
 
• 18 years old 
• In good general health (no current or recent symptoms of illness) 
• No history of gastrointestinal disorder 
• Not currently taking medication 
• Not currently taking vitamin supplements 
 
Informed consent was obtained from all participants. 
 
3.2.3 Blood collection 
Participants were asked to refrain from eating or drinking (other than water) for eight 
hours prior to blood collection, this was to ensure a baseline reading of vitamin status 
could be measured. Venous blood (17mL) was collected from the forearm using butterfly 
needle safety collection kits, into two 8.5mL Vacutainer serum separator tubes. All 
samples were maintained on ice until laboratory processing. Serum separator tubes were 
centrifuged at 2000g for ten minutes as per the manufacturer’s instructions. The serum 




3.2.4 Saliva collection 
All samples were collected in the morning to minimise circadian variance. Resting saliva 
was sampled by expectoration into pre-weighed universal tubes over ten minutes. Tubes 
were re-weighed in order to calculate saliva secretion rate. Salivary mass was assumed 
equal to volume (1g=1mL). Salivary flow rate was calculated by multiplying the assumed 
volume of collected saliva, by the duration of collection, flow rate is expressed as mL/min.  
Samples were stored on ice until processing. Saliva samples were centrifuged at 
13,000g for 5 minutes at 4ºC to remove any cellular or microbial debris. Samples were 
divided into aliquots of 200L and stored at -80C until testing. 
 
3.2.5 Sample analysis 
For greater detail on sample analysis please refer to Chapter 2. In brief, vitamin-binding 
proteins; haptocorrin, vitamin D-binding protein, and retinol-binding protein were 
quantified by ELISA in saliva and serum samples. Salivary total protein content was 
measured by BCA assay in order to load equal total protein on SDS-PAGE. Vitamin-
binding proteins were detected by immuno-blot. 25-OH-D and total-vitamin B12 were 
quantified in serum by CMIA, as indicators of vitamin D and B12 status respectively. 
Retinoic acid was quantified by HPLC as an indicator of vitamin A status. 
 
3.2.6 Statistical analysis 
Correlation was analysed by linear regression with goodness of fit demonstrated by R2-




3.3 Results  
3.3.1 Cohort summary 
No statistically significant differences were observed between male and female 
participants for any of the parameters in Table 3-1 when analyses by t-test. Salivary 
vitamin D-binding protein concentration did appear to be more variable in the female 
cohort (raw demographic data is presented in Appendix 1).  
 
3.3.2 Salivary vitamin-binding proteins 
Figure 3-1 confirms by immuno-blot, the presence of vitamin D-binding protein, 
haptocorrin, and retinol-binding protein in resting whole mouth saliva previously 
demonstrated by proteomic analysis (141). Samples were normalised by total protein 
concentration prior to electrophoresis to account for interpersonal variation. A number of 
samples have particularly strong signals in comparison to the remainder, for example C-
i, J-i, and E-ii.  
  Female Male Aggregate 
n 6 8 14 
 
Mean  SEM 
Age 30.292.76 31.754.69 30.292.76 
Resting salivary flow rate (mL/min) 0.460.05 0.440.05 0.460.05 
    
Serum [25-OH-D] (nmol/L) 40.008.72 40.758.61 40.435.95 
Salivary [DBP] (ng/mL) 349.00135.60 215.1038.46 268.7058.67 
Salivary DBP output (ng/min) 205.5096.78 88.9217.87 138.9043.57 
Serum [DBP] (g/mL) 376.6053.17 321.7040.52 345.2032.06 
    
Serum [total-B12] (ng/L) 246.5034.53 279.5035.78 265.40 24.72 
Salivary [Hc] (pg/mL) 34.789.05 30.144.77 31.704.77 
Salivary Hc output (pg/min) 69.3915.23 34.187.92 49.279.00 
Serum [Hc] (pg/mL) 545.40171.6 443.10101.20 486.9090.55 
    
Serum [retinol] (mol/L) 1.990.15 2.140.15 2.080.10 
Salivary [RBP] (g/mL) 1.440.10 1.440.11 1.440.08 
Salivary RBP output (g/min) 0.510.07 0.790.14 0.670.09 
Serum [RBP] (g/mL) 95.171.60 90.733.49 96.632.13 
 
Table 3-1 Vitamin-binding protein concentrations and secretory outputs in saliva, 





3.3.3 Vitamin D and vitamin D-binding protein 
Figure 3-2 represents the distribution of vitamin D-status in the study cohort (raw values 
can be found in Appendix 2. 25-hydroxyvitamin D (25-OH-D) is a robust and stable 
marker of vitamin D status (207). Reference ranges vary; however, serum 25-OH-D 
concentrations are commonly divided into the following three categories of sufficient 
(>50nmol/L), insufficient (30-50nmol/L), and deficient (<30nmol/L) (208). The incidence 
of deficient and insufficient participants in this cohort although striking for a group of 
healthy individuals has been previously reported by a number of large-scale 
epidemiological studies (44).  
 
Figure 3-3 demonstrates the correlation analysis of serum, and salivary vitamin D-
binding protein (DBP) concentration, and salivary DBP output (raw value can be found 
in Appendix 2). Serum DBP concentration (left Y-axis) and 25-OH-D showed the 







Figure 3-1 Detection of salivary vitamin-binding proteins by immunoblot.  
Resting unstimulated whole mouth saliva samples from 14 study participants (A-N). Blots 
immunoprobed for (i) vitamin D-binding protein, (ii) haptocorrin, and (iii) retinol binding protein. 
Figure 3-2 Distribution of vitamin D status in the study cohort.  
Determined by serum 25-OH-D concentration (nmol/L). Grey-scale of data points is descriptive of 





























strongest relationship although this is not quite significant (R2 0.26, p 0.06). Salivary 
DBP, concentration and output shared no clear relationship with vitamin D status. 
Furthermore, the serum concentration of DBP is observed here approximately 1000-fold 
higher than that of saliva, which is not uncommon for proteins shared between the two 
biofluids (1).  
 
 
A positive relationship was observed between DBP concentration in the two biofluids 
(Figure 3-4) (raw values can be found in Appendix 2) of R2 0.33 (p 0.03) suggesting 
expression is regulated in the same manner, or salivary DBP is a serum contaminant. 
The relationship with salivary DBP output was even stronger with R2 0.45 (p 0.01).  
Figure 3-3 The relationship between 25-OH-D, and circulatory and salivary vitamin 
D-binding protein.  
Individual values and line of best fit presented. Correlation analysis of serum and salivary vitamin 
D-binding protein (DBP) concentration and output against the commonly used marker of vitamin 
D status, 25-hydroxyvitamin D (nmol/L). (a) Serum DBP concentration (µg/mL) (left axis) R2 0.26 
(p 0.06). (b) Salivary DBP concentration (ng/mL) (right axis) R2 0.11 (p 0.25). (c) Salivary DBP 
output (ng/min) (right axis) R2 0.14 (p 0.18). 
 























































































3.3.4 Vitamin B12 and haptocorrin 
Figure 3-5 illustrates the distribution of vitamin B12 status in the study cohort. Fasting 
serum samples were used to measure total-vitamin B12 concentration. Three study 
participants were below the lower threshold of healthy vitamin B12 status. The commonly 





















































Saliva DBP Output ng/min
0.0089
n = 14
Figure 3-4 The relationship between serum vitamin D-binding protein 
concentration and salivary concentration and output 
Individual values and line of best fit presented. Correlation analysis of salivary vitamin D-binding 
protein (DBP) concentration and output against serum DBP concentration (µg/mL). (a) Salivary 
DBP concentration (ng/mL) R2 0.33 (p 0.03). (b) Salivary DBP output (ng/min) R2 0.45 (p 0.01). 
 
Figure 3-5 Distribution of vitamin B12 status in the study cohort.  
Determined by total serum vitamin B12. Grey points indicate a value outside of the “healthy’ 





























used reference range of 187-883ng/L represented with grey points for individuals outside 
of that range. This reference range for diagnostic purposes is not infallible, with some 
individuals within this range, reported to manifest signs of deficiency, however for the 
purpose of correlation in this study, total-vitamin B12 was deemed a valid marker.  
 
Figure 3-6 represents the correlation analysis between total-vitamin B12 concentration, 
and that of serum and salivary concentrations of haptocorrin as determined be ELISA. 
The resting salivary output of haptocorrin is also shown, this considers the salivary flow 
rate and can represent the non-static nature of salivary composition. A significant 
correlation was observed between serum haptocorrin concentration and that of total-B12 
with an R2 value of 0.50 (p <0.01). Salivary haptocorrin concentration, and output 




No significant relationship was found between the concentration of haptocorrin in serum 
or saliva, or between serum concentration and salivary Hc output (Figure 3-7). 
Figure 3-6 The relationship between vitamin B12, and circulatory and salivary 
haptocorrin. 
Individual values and line of best fit presented. Correlation analysis of serum and salivary 
haptocorrin (Hc) concentration and salivary output against total serum vitamin B12 (ng/L), a 
commonly employed marker of vitamin B12 status. (a) Serum Hc concentration(pg/mL) R2 0.50 (p 
< 0.01). (b) Salivary Hc concentration (pg/mL) R2 0.08 (p 0.33). (c) Salivary Hc output (pg/min) 
R2 0.15 (p 0.18). 



































































3.3.5 Vitamin A and retinol-binding protein 
Figure 3-8 shows the distribution of serum retinol concentration, which was used as a 
marker of vitamin A status (raw data can be found in Appendix 4). A commonly used 
reference range for retinol is 1.4-3.84mol/L for which all participants were within.  
Figure 3-7 The relationship between serum haptocorrin concentration and 
salivary concentration and output 
Individual values and line of best fit presented. Correlation analysis of salivary haptocorrin (Hc) 
concentration and output against serum Hc concentration (pg/mL). (a) Salivary Hc 
concentration (pg/mL) R2 0.02 (p 0.61). (b) Salivary Hc output (pg/min) R2 <0.01 (p 0.81). 
 






















































Figure 3-8 Distribution of vitamin A status in the study cohort.  
























Figure 3-9 demonstrates a significant relationship between retinol, and serum retinol-
binding protein (RBP) concentration with an R2 of 0.48 (p <0.01) (left Y-axis). No clear 
relationship was seen between retinol and salivary RBP concentration or output. Salivary 





No significant relationship was seen between serum retinol-binding protein 




Figure 3-9 The relationship between vitamin A, and circulatory and salivary retinol-
binding protein.  
Individual values and line of best fit presented. Correlation analysis of serum and salivary retinol-
binding protein (RBP) concentration and output against circulatory retinol (mol/L). (a) Serum 
RBP concentration (g/mL) (left axis) R2 0.48 (p < 0.01). (b) Salivary RBP concentration (g/mL) 
(right axis) R2 0.04 (p 0.50). (c) Salivary RBP output (g/min) (right axis) R2 0.02 (p 0.60). 



























(b) Salivary [RBP]  


















































Figure 3-11 demonstrates a statistically significant inverse association between age and 
salivary retinol-binding protein concentration and output. This differed from salivary flow 
rate, and total salivary protein concentration which showed no significant relationship 
with age of participants. No other parameter in this study demonstrated a significant 
correlation with age (Appendix 5). 
 




















































Saliva RBP output /µgmin 
0.3014
Figure 3-10 The relationship between serum retinol-binding protein concentration 
and salivary concentration and output  
Individual values and line of best fit presented. Correlation analysis of salivary retinol-binding 
protein (RBP) concentration and output against serum RBP concentration (µg/mL). (a) Salivary 





Figure 3-11 Age-associated differences in salivary retinol-binding protein 
concentration and output.  
Individual values and line of best fit presented. Correlation analysis of participant age (years) and 
(a) resting salivary flow rate (mL/min) R2 <0.01 (p 0.99). (b) Salivary retinol-binding protein (RBP) 
concentration (µg/mL) R2 0.61 (p <0.01). (c) Salivary RBP output (µg/min) R2 0.44 (p 0.01). (d) 
Serum RBP concentration (µg/mL) R2 <0.01 (p 0.99). (e) Serum retinol (µmol/L) concentration R2  
0.12 (p 0.74). 
 







(a) Resting salivary flow rate
(b) Salivary [RBP] 

















































































(e) Serum [retinol] 
















Whole mouth saliva is a complex easily assessible biofluid, with a catalogue of over two 
thousand protein constituents (141). Approximately 27% of the salivary proteome is 
shared with that of plasma (198). Consequently; the diagnostic potential of saliva for 
systemic diseases is a popular area of research. The work in this initial chapter examined 
the relationship between commonly used clinical markers of vitamin status, and vitamin-
binding proteins present in both saliva and blood. 
 
No statistically significant differences were noticed between male and female 
participants in this study; however, greater variance was seen in vitamin D-binding 
protein output in the female cohort. There is some evidence in the literature to suggest 
the use of hormonal contraceptives may influence plasma concentrations of vitamin D 
metabolites and DBP (209). Although our data does not suggest this for serum, salivary 
gland expression of DBP may be influenced by hormonal contraceptives, which has been 
demonstrated previously for other salivary constituents (210, 211). Future studies of a 
similar nature should take the use of hormonal contraceptives into account.  
 
The distribution of serum 25-OH-D concentrations, and the incidence of insufficiency and 
deficiency in this study is quite striking, though not dissimilar to published studies which 
have reported approximate hypovitaminosis D prevalence of 50% in British adults (212). 
In this study, salivary DBP concentration did not correlate as well as serum DBP to 
circulatory 25-OH-D, however salivary and serum DBP did correlation to each other, with 
approximately 2000-fold difference in concentration. Circulatory DBP is largely 
expressed by hepatocytes, however the source of salivary DBP remains unclear (213). 
One challenge in studying dietary vitamin D uptake arises from endogenous synthesis. 
Dissimilar to the other twelve vitamins, vitamin D can by synthesised in the dermis by 
UV-B irradiation of 7-dehydrocholesterol, which yields pre-vitamin D, and over time at 
body temperature this is converted to vitamin D (22). The trend between salivary and 
serum DBP concentrations could suggest that it enters saliva from the circulation or 
salivary gland expression of DBP is under the same regulation as the systemic sources 
of the protein. 
 
The importance of salivary and gastric haptocorrin (Hc) has long been suggested for the 
early assimilation pathway of biologically active cobalamin metabolites (79, 214, 215). In 
the digestive tract, Hc offers two key roles, firstly in protecting all corrinoids (cobalamin 
and its analogues) from hydrolysis in the acidic milieu of the stomach (79). Secondly, Hc 
acts as a selective sieve by promiscuously binding corrinoids, and not dissociating from 
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biologically inactive analogues. As a consequence, these complexes are not absorbed 
in the gastrointestinal tract and are excreted (93, 216). The results in this chapter suggest 
salivary haptocorrin did not correlate with total serum vitamin B12, however serum Hc 
concentration did. The correlation between serum Hc concentration and total-B12 is not 
unexpected with approximately 70-80% of circulatory B12 being bound to haptocorrin 
(217). The lack of relationship observed between salivary and serum Hc concentrations 
suggests it is actively added to saliva and is not simply passive exudation from the 
circulation. A surprising observation from this data however, is the similarity in Hc 
concentrations between saliva and serum samples, often proteins which feature in the 
proteomes of both biofluids are typically a thousand-fold lower in the former, the 
concentrations in the two fluids did not correlate significantly (138). 
 
Retinol-binding protein, occasionally referred to as retinol-binding protein 4, is the sole 
circulatory transporter with specificity for vitamin A and its metabolites. Expression of 
RBP is predominantly undertaken by hepatocytes (218). Serum RBP concentration 
correlates well with serum retinol, however salivary RBP concentration does not. As with 
the lack of correlation identified with the other two vitamin-binding proteins present in 
saliva, the results in this chapter highlight questions on the regulation and source of these 
proteins in the oral cavity. Furthermore, an inverse association was seen between 
salivary RBP and age, it is possibly a consequence of the small sample size or altered 
expression of RBP by salivary glands with age (219).  
 
The results in this chapter demonstrate no clear correlation between salivary vitamin-
binding protein concentration or output and corresponding markers of vitamin status. 
These data do raise questions regarding the source, and indeed function of these 





Chapter 4 Characterisation of vitamin-binding proteins in the 
context of the oral cavity  
 
4.1 Rationale 
The ability of saliva to facilitate the diverse functions of the oral cavity is, in part, due to 
multifunctional properties of the proteins in saliva (220). In addition, the composition, and 
properties of whole mouth saliva demonstrate circadian variance (147, 221). Salivary 
haptocorrin for example, is capable of binding both physiologically active, and inactive 
forms of vitamin B12 which occurs upon liberation from the food matrix in the upper 
digestive tract. The binding affinity of haptocorrin for cobalamin is 50- fold greater than 
other cobalamin-binding proteins in the GI lumen and the highly glycosylated structure 
of haptocorrin is thought to protect the vitamin from hydrolysis in the acidic milieu of the 
stomach lumen (80). Haptocorrin is then cleaved by pancreatic proteases, allowing 
binding by intrinsic factor, which facilitates absorption across the brush boarder (222). 
Most of the literature supporting the hypothesised role of haptocorrin in vitamin 
assimilation, is based on biochemical and biophysical studies, yet do not consider their 
physiological source, or concentration of the vitamin-binding proteins.  
 
Since whole mouth saliva is a mixture of glandular saliva and serum exudate from the 
gingival margin, it should be established if vitamin-binding proteins are made and actively 
secreted by salivary glands or simply a leakage product from blood. An assimilatory role 
for the other vitamin-binding proteins such as vitamin D-binding protein and retinol-
binding protein has yet to be proposed. If assimilation of vitamins is the main role of the 
vitamin-binding proteins it might be expected that they would be synthesised by the 
parotid glands as these are the most up-regulated when salivary flow is stimulated by 
taste and mastication stimuli (1). 
 
4.2 Aims 
To measure salivary vitamin-binding protein concentration and output at rest and during 
stimulated flow, to understand actual amounts of binding proteins. The secondary aim of 
this study was to quantify vitamin-binding protein concentrations in different saliva types 





4.3.1 Ethical approval  
Ethical approval for this study was obtained from the Biomedical Sciences, Medicine, 
Dentistry and Natural and Mathematical Sciences subcommittee of the King’s College 
London Research Ethics Committee (Reference: BDM/14/15-61), and subsequent 
amendment granted 24th January 2018. 
 
4.3.2 Participant recruitment and informed consent 
Potential participants were recruited from within the university, via the research 
recruitment email system. An individual’s compatibility for the study was dependent on 
the following criteria; 
 
• 18 years old 
• In good general health (no current or recent symptoms of illness) 
• No history of gastrointestinal disorder 
• Not currently taking medication 
• Not currently taking vitamin supplements 
 
Informed consent was obtained from all participants. 
 
4.3.3 Comparing resting and mastication stimulated saliva 
Five female, and five male “healthy” participants were recruited. “Healthy” being defined 
as no current or recent symptoms of illness, and not currently taking prescription 
medication. Participants also declared no recent vitamin supplement use.  
Resting saliva was sampled by expectoration into pre-weighed universal tubes over five 
minutes. Tubes were re-weighed to calculate saliva secretion rate. With 1mL volume 
assumed for 1g of weight. There are a number of commonly employed methods for saliva 
stimulation including mastication; typically, of a flavourless gum, citric acid or by 
stimulation by other tastants, or olfaction (223). Mastication of a flavourless gum was 
selected to best replicate the stimulation which would occur consuming foods containing 
the three vitamins of interest. Participants were then asked to chew a flavourless paraffin 
gum until they reported an increase in the salivary flow rate, then swallow the saliva, and 
while continuing to chew expectorate for a further five minutes into another pre-weighed 





4.3.4 Glandular vitamin-binding protein contributions 
One female and one male participant (30yo and 26yo, respectively) were recruited 
following the same eligibility criteria stated above. Unstimulated whole mouth saliva 
(WMS) was collected by expectoration into a pre-weighed universal tube for a duration 
of three minutes. Resting parotid saliva was collected by attaching Lashley cups (King’s 
Medical Science, U.K.) to both the right and left papillae of the Stensen’s ducts (parotid 
ducts) which are located in the buccal mucosa, adjacent to the second superior molar 
(refer to Figure 4-1).  
 
The mouth was rinsed gently for thirty seconds with water. Unstimulated parotid saliva 
was collected for ten minutes, at the same time whole mouth saliva was collected by 
expectoration into a pre-weighed universal tube, this will be referred to as whole mouth 
saliva (non-parotid) (WMS (NP)). Saliva was stimulated by mastication, using flavourless 
gum. Right and left parotid saliva and WMS(NP) were collected for three minutes when 
increase flow was noticed. Finally, upon removal of the Lashley cups, stimulated whole 
mouth saliva was collected by expectoration for a duration of three minutes. All samples 









Figure 4-1 Collection of parotid gland secretion by the Lashley cup method 
(1) Suction cup which attaches to the Stensen’s duct papillae 
(2) Tube carrying glandular secretion 
(3) Tube providing suction to hold the cup in place and prevent contamination or loss of 
secretion 
(4) Universal tube for saliva collection 
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Due to the small sample size, and high degree of interpersonal variation within sample 
types, each participant’s sample set was expressed as a percentage of resting WMS 
concentration.  
 
4.3.5 Saliva analysis 
For more detail on sample analysis please refer to Chapter 2 materials and methods. In 
brief, saliva samples were centrifuged at 13,000g for five minutes at 4C. Vitamin D-
binding protein, haptocorrin, and retinol-binding protein were quantified in all sample 
types by ELISA. Salivary total protein content was measured by BCA assay, haptocorrin 
was also visualised by western blot. 
 
4.3.6 Statistical analysis 
Distribution of the data was determined by D’Agostino & Pearson normality test; all data 
were normally distributed. Paired t-tests were used for the comparison of resting and 




4.4.1 Comparing resting and stimulated whole mouth saliva 
Table 4-1 demonstrates the mean increase in salivary flow rate upon stimulation, this 
was coupled with a small yet significant decrease in total protein concentration. The total 
protein output which is the flow multiplied by concentration however, increased 
significantly upon mastication stimulation. Gender demonstrated no effect on any of the 











Flow rate (mL/min) 0.700.09 1.950.29 p <0.01 
Total protein concentration (mg/mL) 1.660.16 1.290.11 p <0.05 
Total protein output (mg/mL) 1.090.08 2.350.31 p <0.01 
Paired t-test results presented comparing resting to stimulated 




4.4.2 Vitamin D-binding protein 
For the majority of participants in this study (eight out of ten), salivary vitamin D-binding 
protein was lower in concentration in stimulated whole mouth saliva compared to 
stimulated (Figure 4-2 (a)). Two participants demonstrated an increase in DBP 
concentration with mastication. No significant difference was observed between resting 
and stimulated DBP concentration for the cohort as a whole assessed by paired t-test. 
Figure 4-2 (b) presents the change in salivary DBP output between resting and 
stimulated flow and considers the increase in flow rate with mastication. Whole mouth 
DBP output increased significantly for all participants when assessed by paired t-test (a 
table of raw values can be found in Appendix 8). 
 
To understand which of the major salivary glands secrete most of DBP, Figure 4-3 
presents salivary vitamin D-binding protein concentration (a), and output (b), for two 
participants (one male and one female) expressed as a percentage of each individuals 
WMS concentration or output respectively. Normalisation was undertaken in order to 
account for inter-personal variation in DBP concentration. Whole mouth saliva (WMS), 
right and left parotid, and whole mouth saliva excluding parotid (WMS(NP)) were 
collected at resting and mastication stimulated flow. The first observation to make from 
these data, is the difference between the two participants, with participant two having 
greater DBP concentrations and outputs in all saliva categories. Complimentary to Figure 
4-2 (a), stimulated DBP concentration both increased and decreased marginally from the 
resting concentration between the two participants. The mean across participants 
Figure 4-2 Salivary vitamin D-binding protein concentration and output at resting 
and stimulated flow measured by ELISA.  
(a) Subject paired salivary vitamin D-binding protein concentration at resting flow and with 
mastication stimulation  
(b) Subject paired salivary vitamin D-binding protein output (flow x concentration) at rest 






































































however, remained comparable to the resting concentration. Left and right parotid saliva 
from both participants demonstrated a decrease in concentration upon stimulation, 
though considering the large increase in flow rate (please refer to Appendix 11) with 
stimulation, the DBP output from the two parotid glands (Figure 4-3 (b)) remained 
consistent. The greatest source of DBP in stimulated whole mouth saliva was not parotid 
in origin as indicated by WMS(NP) Figure 4-3 (b), this is most acutely apparent in 
WMS(NP) output (b) (raw data is summarised in Appendix 11). 
 
Figure 4-3 Relative salivary vitamin D-binding protein concentration and output by 
saliva type, measured by ELISA. 
Individual measurements expressed as a percentage of resting WMS, means are also presented 
(a) Salivary vitamin D-binding protein concentration of two participants at resting and 
mastication stimulated flow for whole mouth saliva (WMS), left and right parotid glands, 
and whole mouth saliva excluding parotid (WMS(NP)), each sample expressed as a 
percentage of WMS. 
(b) Salivary vitamin D-binding protein output for two participants at resting and mastication 
stimulated flow for whole mouth saliva (WMS), left and right parotid glands, and whole 





































































































When visualised by western blot (Figure 4-4), the haptocorrin resting (R) band intensity 
is greater for most (8 participants) of the 10 participants (A-J) than in saliva stimulated 
by mastication (S). Equal volumes of each sample were loaded onto the SDS-PAGE gel. 
These results were later confirmed by ELISA and are represented in Figure 4-5 (a), which 
demonstrates a highly significant decrease in salivary haptocorrin concentration between 
resting and stimulated saliva for the same 10 participants. Data presented a normal 
distribution and therefore were analysed by paired t-test. Figure 4-5 (b) represents 
salivary haptocorrin output of the 10 participants, calculated by multiplying haptocorrin 
concentration by the salivary flow rate. Salivary haptocorrin output increased significantly 
with mastication stimulation. (raw values can be found in Appendix 9).  
 
(i)   ~49kDa 
~49kDa 
MWS           AR   AS   BR     BS   CR    CS     DR   DS   ER     ES   MWS 
(ii)   ~49kDa ~49kDa 
MWS          FR   FS    GR    GS   HR    HS    IR     IS     JR     JS   MWS 
Figure 4-4 Immunoblot of salivary haptocorrin, at resting and stimulated flow. 
Participants A-J, illustrating the difference in haptocorrin concentration, when equal volume is 
loaded between resting (R) and mastication stimulated (S) whole mouth saliva samples. (MWS – 
molecular weight standard) 
 
Figure 4-5 Salivary haptocorrin concentration and output at resting and stimulated 
flow, measured by ELISA.  
(a) Subject paired haptocorrin concentration at resting flow and with mastication stimulation 
( = p <0.001).  
(b) Subject paired salivary haptocorrin output at resting flow and mastication stimulated ( = 





































































Hc concentration decreased but increased in output for the two participants represented 
in Figure 4-6. Both participants demonstrated higher concentrations in resting right and 
left parotid secretions compared to stimulated. The trend in WMS(NP) Hc concentration 
(Figure 4-6 (a)) between rest and stimulated flow was inverse between participants. Hc 
output for both participants, and all saliva categories increased with stimulation (Figure 
4-6 (b)) and demonstrated the majority of Hc output was not parotid in origin (raw data 
is presented in Appendix 11). 
 
Figure 4-6 Relative salivary haptocorrin concentration and output by saliva type, 
measured by ELISA. 
Individual measurements expressed as a percentage of resting WMS, means are also presented 
(c) Salivary haptocorrin concentration of two participants at resting and mastication 
stimulated flow for whole mouth saliva (WMS), left and right parotid glands, and whole 
mouth saliva excluding parotid (WMS(NP)), each sample set expressed as a percentage 
of WMS. 
(d) Salivary haptocorrin output for two participants at resting and mastication stimulated flow 
for whole mouth saliva (WMS), left and right parotid glands, and whole mouth saliva 




































































































4.4.4 Retinol-binding protein 
With mastication-stimulated flow, retinol-binding protein concentration decreased in 60% 
of participants when compared to resting concentration (Figure 4-7 (a)), though no 
significant difference was detected between the categories when assessed by paired t-
test. A significant increase was found in RBP output (Figure 4-7 (b)); however, this 
increase was not consistent for all participants.  
 
RBP concentration and output both increased with stimulation in Figure 4-8 (raw values 
can be found in Appendix 10). The trend in RBP concentration by the parotid glands at 
rest and stimulated flow is unclear, with participant 1 demonstrating an increased RBP 
concentration with stimulation from the right parotid gland alone (Figure 4-8). RBP output 
between parotid and non-parotid saliva demonstrate modest increases with mastication 
(raw data is presented in Appendix 11). 
Figure 4-7 Salivary retinol-binding protein concentration and output at resting 
and stimulated flow, measured by ELISA. 
(a) Subject paired RBP concentration at resting flow and with mastication stimulation  
(b) Subject paired salivary RBP output at resting flow and mastication stimulated ( = p 









































































Results in this section indicate all three vitamin-binding proteins studied were detectible 
components of salivary gland secretions. Examining a salivary protein concentration 
alone is insufficient as concentration is dependent on salivary flow which is variable, 
even within a single subject, and expresses circadian variance (224, 225). All three 
proteins increased significantly in output when salivary flow was upregulated by 
mastication. Of the vitamin-binding proteins focused on in this study, salivary haptocorrin 
has been the most reported in the literature to contribute to the assimilation pathway of 
its vitamin ligand (79). Haptocorrin is considered to play a role in protecting vitamin B12 
from hydrolysis during gastric processing of food; however, understanding the output of 
salivary haptocorrin and the other salivary vitamin-binding proteins during different 
stimulatory states has been neglected. Indeed, there have been reported cases of 
haptocorrin deficiency with no associated hypovitaminosis B12, further questioning the 
significance of haptocorrin to vitamin B12 assimilation (226). Of the three pairs of major 
salivary glands, the rate of parotid gland secretion is the most up regulated when 
stimulated by mastication (223). Consequently; it might be expected that parotid glands 
would synthesis the majority of vitamin-binding proteins if they exert a function in vitamin 
assimilation. The major salivary glands are preferential innervated by different nerves 
Figure 4-8 Relative salivary retinol-binding protein concentration and output by 
saliva type, measured by ELISA. 
Individual measurements expressed as a percentage of resting WMS, means are also 
presented 
(a) Salivary retinol-binding protein concentration of two participants at resting and 
mastication stimulated flow for whole mouth saliva (WMS), left and right parotid 
glands, and whole mouth saliva excluding parotid (WMS(NP)), each sample set 
expressed as a percentage of WMS. 
(b) Salivary RBP output for two participants at resting and mastication stimulated flow for 
whole mouth saliva (WMS), left and right parotid glands, and whole mouth saliva 





































































































and activated, to varying extents, by different stimuli. For example, olfaction only 
stimulates submandibular and sublingual glands. Whereas food (by taste and 
mastication) upregulates parotid glands more than submandibular or sublingual, the 
parotid glands contribute to 58% of salivary volume with mechanical stimulation 
compared to 21%, with no stimulation, or 45% with citric acid stimulation (227).  
 
4.5.1 Salivary vitamin D-binding protein 
Vitamin D-binding protein is highly abundant in the circulation, predominantly hepatically 
expressed, with a low degree of transcription occurring in extra-hepatic tissues such as 
kidney, testis and abdominal adipose (32). The data presented in Chapter 3 
demonstrated salivary DBP concentration was 1000-fold lower than that of serum, DBP 
concentrations across the two biofluids shared a positive relationship. DBP was initially 
identified as a salivary constituent in the 1980s, being recognised in parotid secretions 
by crossed immunoelectrophoretic mapping (228). The work presented in this chapter 
supports the work of Krayer et al. who quantified DBP to a range of ~1-100ng/mL in 
whole mouth and parotid saliva by ELISA (140). No clear change in whole mouth salivary 
DBP concentrations between rest and chew stimulated flow was found; however, DBP 
output did increase with stimulation. The parotid contribution however, (Figure 4-3) 
decreased in concentration with stimulation but maintained its output, thus suggesting 
DBP does not enter the parotid secretion as a typical acinar product. Instead DBP in 
parotid secretions may be secreted by ductal cells, which would allow DBP concentration 
to gradually increase at resting flow but would be diluted with stimulation.  
 
The greatest source of DBP in whole mouth saliva is non-parotid in origin as 
demonstrated in Figure 4-3. Data presented in Figure 3-3 represents a positive 
relationship between salivary and serum DBP, Figure 4-3 in this chapter demonstrated 
the majority of WMS DBP was not parotid in origin. The WMS(NP) samples in this study 
would contain secretions from the sublingual and submandibular glands, minor gland 
saliva, and contaminants from the gingival crevicular fluid (GCF). GCF is a serum 
exudate which pools in the gingival sulcus. The periodontium is a highly vascularised 
tissue allowing the migration of circulatory molecules and cells out of blood vessels into 
the tissue (229). Being a serum exudate, GCF greatly reflect the composition of serum 
and in a healthy state contains an even greater concentration of DBP than that of serum 
(141). The method of stimulation in this study may be responsible for the large increase 
in WMS(NP) DBP between rest and stimulated demonstrated in Figure 4-2. Mastication 
increases salivary concentration of epithelial and microbial cell output and could increase 
the flow of GCF contamination, the high DBP concentration in GCF, could therefore be 
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responsible for the observed increases with mastication (230). Inflammation of the 
periodontium can result in a faster rate of exudation from the circulation (231, 232), and 
therefore GCF may have a higher concentration of serum components, this may be 
responsible for the dichotomous inter-personal trends observed in Figure 4-2 (a). In 
addition to its role in vitamin D transport, vitamin D-binding protein has been 
demonstrated to have immunomodulatory functions, enhancing the chemotactic activity 
of the complement pathway components C5a and C5adesArg (40), as well as scavenging 
actin-monomers, preventing filamentation which may occlude the vasculature (233). An 
abundance of DBP in the GCF may have a protective role for the periodontium. 
 
4.5.2 Salivary haptocorrin 
Figure 4-5 (a) demonstrates whole mouth salivary haptocorrin consistently decreased in 
concentration with mastication stimulation, Hc output did however, increase with 
stimulation. This appears to be consistent for parotid and non-parotid secretions, 
implying expression by salivary gland ductal cells. Haptocorrin has been detected by 
others in saliva, and immunohistochemically in both ductal and acinar mucous cells of 
salivary glands (234-236). Since the parotid glands do not contain mucus acini, they 
would produce less haptocorrin than the submandibular and sublingual glands. This may 
suggest that haptocorrin has additional roles to the assimilation of vitamin B12 because 
of the continual secretion of haptocorrin without stimulation.  
 
Haptocorrin is not responsible for vitamin B12 absorption across the gastro-intestinal 
epithelium; indeed, a failure to proteolytically dissociate Hc from vitamin B12 in the 
duodenum can lead to malabsorption (81, 226). Instead an homologous binding protein 
termed intrinsic factor (IF), binds the released vitamin, and facilitates receptor mediated 
endocytosis in the terminal ileum (79). Unlike the vitamin B12-binding site of IF, that of Hc 
has poor discrimination between the physiologically active and inactive analogues in 
humans (94). Hc has been identified in a number of exocrine secretions in addition to 
saliva such as tears, milk, nasal secretion, and seminal plasma (237-239). Furthermore, 
haptocorrin is a component of neutrophil secretory granules along with the iron 
sequestering protein, lactoferrin (226). This conserved secretion onto numerous mucosal 
surfaces and the non-selective ability to scavenge vitamin B12 analogues may suggest 
an antimicrobial function. 
 
4.5.3 Salivary retinol-binding protein 
Retinol-binding protein has been detected in parotid secretions by others (240). Figure 
4-7 and Figure 4-8 indicate the output of RBP increased with mastication stimulation, the 
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parotid saliva also contained RBP which is complimentary to the aforementioned study. 
RBP is an abundant circulatory protein predominantly expressed by hepatocytes, RBP 
transcripts however, have also been detected in adipose tissue, and to a lesser extent 
renal tissue (125). Structurally RBP exhibits a single binding site for all-trans retinol, and 
is complexed to transthyretin in the circulation which increases the collective molecular 
weight, reducing the degree of glomerular filtration (121). Being a lipid soluble vitamin, 
the orientation of the hydrophobic domains of the molecule are shrouded within a beta-
barrel hydrophobic pocket, which increases the solubility of the complex (240). As with 
DBP, the trend in salivary RBP concentration between resting and mastication stimulated 
flow varied between participants (Figure 4-7 (a)). This variance may be a consequence 
of gingival inflammation, and increased contamination from the circulation. Previous 
studies have detected RBP in mouse salivary glands; however, localisation within the 
tissue was not determined (241). The circulatory concentration of RBP demonstrated in 
Figure 3-9 correlates well with vitamin A status; indeed, there is literature which shows 
hepatocytes expression of RBP is driven by retinol status (242). Figure 3-9 shows a lack 
of correlation between salivary RBP and retinol which questions the role of retinol in 
regulating the expression of RBP in extra-hepatic tissues. 
 
4.5.4 Summary 
The work presented in this chapter indicated that DBP, Hc, and RBP all increased in 
whole mouth saliva output with mastication stimulation suggesting they are secreted by 
salivary glands, although which cell type may differ between the three proteins and 
glands. These data demonstrate that there would be large amounts of the three proteins 
during digestion, furthermore high concentrations even at resting salivary flow, may 






Chapter 5 The influence of periodontal disease on salivary 




Periodontal disease is a chronic inflammatory disorder affecting the supportive tissues 
of the dentition (periodontium). The aetiology of periodontal disease is considered to be 
a disruption of homeostasis in the tissues adjacent to the multispecies biofilms (plaque) 
which form on the enamel pellicle (168). There remains a lack of clarity as to the initial 
cause of periodontal disease, be it host, or microbial. A number of bacterial species 
demonstrate a strong association with the disease and have subsequently been termed 
the “red complex’ (187, 243). Attributes of these species have been demonstrated to 
dysregulate the typical immune response and maintenance of these tissues. One such 
species is the Gram negative, anaerobic pathobiont Porphyromonas gingivalis, which is 
a common commensal species in plaque, and is frequently enriched in plaque bordering 
sites of gingival inflammation (244). P. gingivalis is considered a keystone species which 
can promote a dysbiotic shift in the microbial community composition (185, 188). A well-
defined virulence factor of P. gingivalis are a group promiscuous trypsin-like cysteine 
proteases termed gingipains (189). 
 
A significant, and current literature has demonstrated strong associations between 
periodontal disease and a range of systemic diseases and health concerns, including 
diabetes and cardiovascular disease (173, 245, 246). A number of studies have 
highlighted the association between micronutrient deficiencies with periodontal disease, 
the most substantiated being hypovitaminosis D, but a number of studies have further 
demonstrated relationships with hypovitaminoses B12 and A (107). The discovery of the 
vitamin D-receptor has greatly broadened understanding of the importance of vitamin D 
for maintaining health, and particularly its role in modulating inflammatory and immune 
responses (64). Retrospective epidemiological studies using large datasets such as 
NHANES have demonstrated inverse associations between a number of vitamins and 
periodontal disease severity (247). A study by Zong et al. (2016) reported an inverse 






To compare concentrations of salivary vitamin-binding proteins, and serum vitamin levels 
in a periodontal disease cohort, before and after treatment, to understand the influence 
of periodontal disease on salivary vitamin-binding proteins and ultimately vitamin status.  
 
5.3 Method 
5.3.1 Ethical approval 
This study used a pre-collected sample set kindly made available for analysis by 
Professor F. Hughes, Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral 
and Craniofacial Sciences. Ethical approval was obtained by Professor F. Hughes, from 
the proportionate review sub-committee of the HR, NRS Committee North East – 
Newcastle, and North Tyneside 2. Rec reference 12/NE/0122.  
 
5.3.2 Study design 
Participants received an initial periodontal examination at baseline, followed by a 
standardised course of nonsurgical periodontal treatment consisting of oral hygiene 
instruction and full mouth subgingival debridement with local anaesthesia. Samples were 
collected at the baseline visit and at follow up visit 10 weeks following completion of 
treatment. All treatment was carried out by the same operator who was an experienced 
trained periodontist (Dr Belkais Abushaia Karim). 
 
5.3.3 Cohort disease characterisation  
All participants were diagnosed with moderate to severe periodontitis according to AAP 
/ CDC case definition criteria (i.e. Patients with two or more interproximal sites with 
clinical attachment loss of ≥ 4mm occurring at two or more different teeth or two or more 
interproximal sites with a probing depth of ≥5mm, not on the same tooth) (248). 
Response to treatment was assessed according to the percentage of deep pockets that 
showed no response to treatment as defined by pocket depth reduction. Poorly-
responding patients were defined as having more that 50% of non-responding deep sites 
(249). 
 
5.3.4 Sample analysis 
Details of specific analyses can be found in greater detail in Chapter 2 Materials and 
methods. In brief, saliva was analysed by ELISA, to quantify vitamin D-binding protein, 
haptocorrin, and retinol-binding protein. Salivary proteins were separated by SDS-PAGE 
electrophoresis, before immunoblotting for vitamin D-binding protein and haptocorrin to 
visualise any obvious indications of degradation. 25-OH-D and total-vitamin B12 were 
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quantified in serum by chemiluminescent microparticle immunoassay (CMIA), as 
markers of vitamin D and B12 status respectively. Retinol was quantified by HPLC as a 
marker of vitamin A status.  
 
Due to limited sample volume it was not always possible to conduct all assays on all 
sample types, full details of sample size per assay can be found in Appendix 13 and 
Appendix 14. 
 
5.3.5 Statistical analysis  
Distribution of all data sets was determined with D’Agostino and Pearson normality test. 
Paired data were analysed with paired t-test, or a non-parametric equivalent (noted in 
results where appropriate). Multiple group analysis was undertaken with ANOVA, and 
multiple comparison tests, specific tests are noted in figure captions.  
 
5.4 Results 
Raw data can be found in Appendix 12. 
 
Aggregate Gender Smoking status 










n 30 17 13 8 11 11 
Age 44.31.62 43.71.76 45.13.03 41.133.19 47.822.48 43.092.73 
 
Table 5-1 Periodontal disease cohort summary 
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5.4.1 Vitamin D and vitamin D-binding protein 
Figure 5-1 is a series of immunoblots of longitudinally paired saliva samples from the 
periodontal disease cohort, before and after treatment, probed for vitamin D-binding 
protein. All samples indicate a band at the correct molecular weight. There is no clear 
indication of degradation, some differences are evident between paired samples before 
and after treatment, for example the band intensity is greater in 12A than 12B, and 23B 
than 23B.  
 
Salivary DBP concentration decreased in 73% of patients after treatment, which was 
statistically significant when analysed by non-parametric, paired statistical analysis 
(Figure 5-2 (a)) (raw data is presented in Appendix 14). 63% of patients had a decrease 
in serum 25-OH-D concentration after treatment, however this was not significant (Figure 
5-2 (b)) (raw data is presented in Appendix 13).  
STN            1A    1B    2A    2B     3A   3B    4A     4B    5A      5B         
STN           6A    6B    7A    7B     8A    8B    9A     9B    10A   10B         
STN            11A  11B   12A  12B  13A 13B   14A   14B  15A   15B    
STN            16A  16B   17A  17B  18A  18B   19A   19B  20A  20B    
STN            21A   21B  22A  22B  23A  23B  24A    24B  25A   25B 







Figure 5-1 Immunoblot of salivary vitamin D-binding protein in a periodontal 
disease cohort. 
(1-30) prior to treatment (A), and post treatment (B). Blot probed for vitamin D-binding protein. 




Compared to the periodontally healthy cohort (Figure 3-3 (a)), DBP concentration was 
significantly higher in the disease cohort post treatment, assessed by non-parametric 
ANOVA, and multiple comparisons test. No difference was found between the healthy 
and disease cohort at either timepoint for serum 25-OH-D concentration (Figure 5-3 (b)). 
The high incidence of 25-OH-D insufficiency (50-30nmol/L) was high in both cohorts 36% 
in the healthy cohort, and 33% in the periodontal disease cohort decreasing to 25% after 
treatment. Deficiency of 25-OH-D (<30nmol/L) was also high in both cohorts with 26% 
of healthy participants deficient, and 45% of periodontal disease patients increasing to 
58% post treatment (Figure 5-3b) (raw data Appendix 13).  
 
  
Figure 5-2 Influence of periodontal disease on salivary vitamin D-binding protein 
concentration, as quantified by ELISA, and circulatory 25-OH-D concentration, 
as quantified by CMIA 
(a) Subject paired salivary vitamin D-binding protein concentration before and after 
treatment for periodontal disease, a significant decrease in DBP concentration is 
observed when analysed by Wilcoxon matched pairs signed rank test ( = p <0.05).  
(b) Subject paired circulatory 25-OH-D concentration before and after treatment for 
























































































No statistical differences in salivary DBP (Figure 5-4 (a)) and serum 25-OH-D Figure 5-4 
(b)) concentrations in patient groups the either responded, or failed to respond to 

























































Figure 5-3 Comparing salivary vitamin D-binding protein and circulatory 25-OH-D 
concentrations between health and disease 
Individual measurements and group means are presented, error bars indicate standard deviation  
(a) Salivary vitamin D-binding protein concentration in a periodontally healthy cohort, 
compared to a periodontal disease cohort before and after treatment. Significant 
difference was seen between the health and after treatment cohorts when assessed by 
Kruskal-Wallis test, and Dunn’s multiple comparisons test ( = p <0.05). 
(b) Circulatory 25-OH-D concentration in a periodontally healthy cohort, compared to a 


































































































Responders (n = 18)







































Responders (n = 22)
Non-responders (n =8)
(a)
Figure 5-4 Differences in salivary vitamin D-binding protein, and serum 25-OH-D  
concentrations in response to periodontal disease treatment 
(a) Salivary DBP concentration before and after treatment for periodontal disease, divided 
by response to treatment  
(b) Serum 25-OH-D concentration before and after treatment for periodontal disease, 




5.4.2 Vitamin B12 and haptocorrin 
Figure 5-5 is a series of immunoblots probed for haptocorrin. Longitudinally paired before 
(A) and after (B) treatment saliva samples of 30 periodontal disease patients. Compared 
to the haptocorrin immunoblot presented in Figure 3-1(ii) from a cohort of periodontally 
healthy individuals, the bands presented in Figure 5-5 are more diffuse and less defined. 
There are multiple examples where the band intensity is greater in the post treatment 
samples such as 2A and B, 5A and 5, and 21A and B. A laddering banding pattern is 
demonstrated in 14A, these observed features may be a consequence of enzymatic 
cleavage of constituents of haptocorrin, be it proteolytic or glycolytic. 
The concentration of salivary haptocorrin was greater in 77% of periodontal disease 
patients after treatment (Figure 5-6 (a)) which was statistically significant. Non-
parametric distribution was determined by D’Agostino & Pearson normality test, and 
subsequently the data were assessed by Wilcoxon matched-pairs signed rank test which 
demonstrated significant difference between the two groups. Total-B12 was quantified in 
serum and demonstrated no clear trend between sample points (Figure 5-6 (b)) with 45% 
STN                   1A   1B    2A    2B     3A    3B     4A   4B   5A   5B         
~48KDa 
STN                   6A   6B    7A    7B    8A    8B    9A   9B   10A  10B         
~48KDa 
STN            11A  11B   12A  12B  13A 13B   14A   14B  15A   15B    
~48KDa 
STN            16A  16B   17A  17B  18A  18B   19A   19B  20A  20B    
~48KDa 
STN            21A   21B  22A  22B  23A  23B  24A    24B  25A   25B 
~48KDa 
26A  26B  27A  27B   28A  28B   29A  29B   30A  30B 
~48KDa 
Figure 5-5 Immunoblot of salivary haptocorrin in a periodontal disease cohort 
(1-30) prior to treatment (A), and post treatment (B). Blot probed for haptocorrin. STN – 




of patients having a greater concentration after treatment. Distribution of the data was 
determined by the aforementioned normality test and the subsequent paired t-test 
indicated no significant difference before and after treatment.  
 
 
Salivary haptocorrin concentration was greater in the periodontal disease cohort when 
compared to controls, both before and after treatment, less significantly so in the latter 
(Figure 5-7 (a)). Conversely, circulatory total-B12 was significantly lower in the healthy 
cohort compared to the disease cohort both before and after treatment (Figure 5-7 (b))  
 
A significantly higher salivary haptocorrin concentration was seen in the periodontal 
disease patient which responded to treatment, no other significant differences were 
found for non-responsive patients, or for serum total-B12 concentration for any cohort 
(Figure 5-8). 
Figure 5-6 The influence of periodontal disease on salivary haptocorrin 
concentration, as quantified by ELISA, and circulatory total-vitamin B12 
concentration, as quantified by CMIA 
(a) Subject paired salivary haptocorrin concentration before and after treatment for 
periodontal disease, a significantly higher concentration was observed after treatment 
( = p <0.001) when analysed by Wilcoxon matched-pairs signed rank test. 
(b) Subject paired circulatory total-B12 concentration before and after treatment for 






















































































Figure 5-7 Comparing salivary haptocorrin and total-B12 concentrations between 
health and disease 
Individual measurements and group means are presented, error bars indicate standard deviation  
(a) Salivary haptocorrin concentration in a periodontally healthy cohort, compared to a 
periodontal disease cohort before and after treatment. Significant difference was 
observed between the healthy cohort, and before treatment ( = p <0.001), and after 
treatment ( = p <0.05), when analysed by Kruskal-Wallis test, and Dunn’s multiple 
comparisons test.  
(b) Circulatory total vitamin B12 concentration demonstrates significant deference between 
the healthy cohort and the periodontal disease cohort before and after treatment ( = p 



























































































































































Figure 5-8 Differences in salivary haptocorrin, and serum Total-B12 
concentrations in response to periodontal disease treatment 
(c) Salivary Hc concentration before and after treatment for periodontal disease, 
divided by response to treatment ( = p <0.05). 
(d) Serum total-B12 concentration before and after treatment for periodontal disease, 




5.4.3 Vitamin A and retinol-binding protein 
No trend was demonstrated in salivary retinol-binding protein concentration between 
sample points (Figure 5-9 (a)), when quantified by ELISA. The data presented a non-
parametric distribution and therefore was assessed with Wilcoxon matched-pairs signed 
rank test, from which no significant difference was detected. Serum retinol concentration 
did not significantly change in the periodontal disease cohort with treatment (Figure 5-9 
(b)). 
 
Figure 5-10 (a) demonstrates no statistical change was observed in salivary retinol-
binding protein concertation between health and disease, when assessed by Kruskal-
Wallis, and Dunn’s multiple comparisons tests. Interestingly serum retinol concentration 
was lower in periodontal disease patients before treatment compared to controls Figure 
5-10 (a). Analysis was undertaken with one-way ANOVA, and Tukey’s multiple 
comparisons tests. 
 
No significant differences were found between treatment responders and non-
responders for either salivary RBP or serum retinol concentrations (Figure 5-11). 
 
Figure 5-9 The influence of periodontal disease on salivary retinol-binding protein 
concentration, as quantified by ELISA, and circulatory retinol concentration, as 
quantified by HPLC 
(a) Subject paired salivary retinol-binding protein concentration before and after treatment 
for periodontal disease, no significant difference between groups 
(b) Subject paired circulatory retinol concentration before and after treatment for periodontal 























































































Figure 5-10 Comparing salivary retinol-binding protein and retinol concentrations 
between health and disease 
Individual measurements and group means are presented, error bars indicate standard deviation  
(a) Salivary retinol-binding protein concentration in a periodontally healthy cohort, compared 
to a periodontal disease cohort before and after treatment.  
(b) Circulatory retinol concentration in the healthy cohort and the periodontal disease cohort 
before and after treatment. Data presented a normal distribution, one-way ANOVA was 


















































































































































Responders (n = 14)
Non-responders (n = 5) 
(a)
Figure 5-11 Differences in salivary retinol-binding protein, and serum 
retinol concentrations in response to periodontal disease treatment 
(a) Salivary RBP concentration before and after treatment for periodontal disease, 
divided by response to treatment  
(b) Serum retinol concentration before and after treatment for periodontal disease, 
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The data presented in this chapter demonstrated that periodontal disease had apposing 
effects on the salivary concentrations of vitamin D-binding protein and haptocorrin, 
revealing a significant increase and decrease, respectively. These changes in salivary 
vitamin-binding protein concentration do not correlate positively with changes in systemic 
markers of vitamin status, and therefore questions the significance of salivary vitamin-
binding proteins in assimilation of their vitamin ligands. 
 
5.5.2 Vitamin D and vitamin D-binding protein 
The results in this chapter suggest periodontal treatment had no influence on 25-OH-D 
status in this cohort, both before or after treatment, or indeed when compared to a 
periodontally healthy cohort. 
 
The literature surrounding sub-optimal vitamin D status and periodontal disease remains 
inconclusive. A number of large epidemiological analyses including the use of the 
National Health and Nutrition Examination Survey 3 (NHANES 3) generated in the USA, 
have identified inverse associations between 25-OH-D status and gingival inflammation 
(56). Vitamin D status at the point of periodontal surgery has been demonstrated to affect 
surgical outcomes, and indeed supplementation with calcium and vitamin D has been 
demonstrated to improve periodontal health in those on periodontal maintenance therapy 
(68, 250). Mechanistically the critical importance of vitamin D for the regulation of calcium 
homeostasis and subsequently bone mineral density has long been known, with clinical 
deficiency presenting systemically as osteopenia and osteoporosis (49). In terms of oral 
health, numerous studies have highlighted the relationship between systemic and oral 
bone mineral density, in particular mandibular and alveolar bone density (251-254). 
Vitamin D acting via the nuclear vitamin D-receptor: VDR, has been shown to attenuate 
osteoclastogenesis and subsequently reduce alveolar bone resorption (255). The 
literature indicates the protective effect of vitamin D may be irrespective of bone mineral 
density (55). Although 25-OH-D is a commonly employed and robust indicator of vitamin 
D status, it is activated by a second hydroxylation step undertaken by 1 -hydroxylase 
which is expressed in gingival tissue. The subsequent 1,25-dihydroxyvitamin D has been 
demonstrated to have immune and barrier functioning attributes, and therefore may offer 
localised immune-protective effects (256, 257). Measuring these two vitamin D 
metabolites in gingival crevicular fluid may offer a better indication to the protective role 




The findings of this chapter indicated a higher whole mouth salivary concentration of 
vitamin D-binding protein (DBP) before treatment. This finding complements a study by 
Krayer et al, which quantified DBP by ELISA in whole mouth, and parotid saliva, and 
noted a greater whole mouth DBP concentration with periodontal disease (140). With 
DBP being highly abundant in both the circulation and GCF, the increase in salivary DBP 
could be a consequence of gingival inflammation and increased contamination from 
these fluids, which has been demonstrated previously for other circulatory proteins (258). 
Interestingly, a study by Zhang et al, observed higher plasma concentration of DBP in 
patients with generalised aggressive periodontitis (199). The trend (positive, or negative) 
in salivary concentrations of DBP between sample points varied between patients, 
although clinically the group were homogenous, the degree of blood contamination at a 
given point may vary between patients and therefore influence the result. 
 
Vitamin D-binding protein is multifunctional. In addition to its vitamin D-binding domain, 
it also possesses a G-actin-binding site and acts to sequester actin-monomers 
preventing unregulated filamentous actin formation (F-actin) (259, 260). G-actin can be 
released into the Interstitium and enter the circulation with tissue injury, and therefore, 
DBP may have a protective role in the periodontium during inflammation by sequestering 
free actin (261). Indeed, the aforementioned Krayer et al, study identified the majority of 
salivary DBP was complexed with G-actin in periodontal disease (140). Salivary DBP 
concentration was collectively lower in those patients which responded to treatment. 
Although this finding was not significant, a greater sample size might be useful to 
demonstrate a difference.  
 
This section of work complements the findings presented in chapter 4.4.2 which 
suggested a significant contribution of salivary DBP was from the gingival crevicular fluid, 
and therefore could be a potential quantitative biomarker for periodontal inflammation, 
or an indicator of response to treatment. The literature highlights the potential importance 
of vitamin D-binding protein in supporting periodontal health.  
 
5.5.3 Vitamin B12 and haptocorrin 
A paper published by Zong et al, in 2016 demonstrated an inverse association between 
serum vitamin B12 status and periodontal disease progression and tooth loss in a cohort 
of >1600 patients with a multivariant regression model. Probing pocket depth (PD) and 
clinical attachment loss (CAL) were used as markers of periodontal disease severity 
(107). The authors did not offer a suggestion on mechanism. The study also found no 
association between smoking and vitamin B12 status which is complimentary to research 
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in this chapter. The findings presented here demonstrated no clear difference in total-B12 
before or after treatment for periodontal disease. However, the periodontal disease 
cohort presented higher serum levels of total-B12 than the periodontally healthy cohort, 
which may be a consequence of dietary differences between the two groups. The 
sensitivity of vitamin B12 biomarkers is an issue which has affected a number of studies 
and has led to a search for more reliable alternatives (262). A recent, more suitable 
biomarker may be holotranscobalamin, which quantifies the fraction of serum B12 bound 
to the circulatory binding protein transcobalamin-II (TCN-II), this is the portion of B12 
available to cells, and has proven to be more sensitive to acute changes in vitamin B12 
status (263). Dissimilar to the other water-soluble vitamins, vitamin B12 is extensively 
stored in hepatic parenchyma, and therefore inadequate intake can take a long time to 
be detected, both biochemically and clinically (264).  
 
In this present study, salivary haptocorrin was observed at a lower concentration in the 
periodontal disease cohort prior to treatment, compared to post treatment. Both these 
sample time points demonstrated lower haptocorrin concentration compared to a 
periodontally healthy cohort. Thus, suggesting periodontal disease may be a driver of 
reduced salivary haptocorrin concentration, possibly as a consequence of proteolytic 
degradation, which is supported by protein band laddering on immunoblots (Figure 5-5). 
A significant increase in post-treatment salivary haptocorrin concentration was observed 
in patients that responded to treatment. The reasoning for disparity in the cohort, with 
regard to treatment outcome is unclear. Salivary haptocorrin is often referred to in the 
literature as an important intermediary protein in the vitamin B12 assimilation pathway 
(79, 214). Although haptocorrin was detected in all samples, there was significantly lower 
concentrations prior to treatment, which had no clear association with vitamin B12 status. 
This could question the significance of salivary haptocorrin to vitamin B12 assimilation or 
could suggest there is an excess of salivary haptocorrin and therefore some degradation 
may not influence assimilation. The gastric mucosa is also a potential source of 
haptocorrin and therefore may add redundancy to salivary haptocorrin (234).  
 
5.5.4 Vitamin A and retinol-binding protein 
Nutritional studies that have focused on periodontal disease have suggested that dietary 
supplementation with antioxidant vitamins including vitamin A, and the previtamin-A 
carotenoids are associated with periodontal disease severity and supplementation can 
support positive treatment outcomes (137, 265). Data presented in this study indicated 
lower circulatory retinol concentration in disease compared to healthy controls, although 
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this was not significant, no difference was observed between controls and disease cohort 
post treatment; the antioxidant properties of vitamin A may contribute to this.  
 
No change in salivary retinol-binding protein (RBP) was observed with treatment for 
periodontal disease, or between control and disease cohorts. The range of salivary RBP 
concentration was greater in the disease cohort compared to control. One study 
identified elevated serum RBP concentration in a periodontal disease cohort, which 
decreased three months after non-surgical treatment (266). RBP in gingival crevicular 
fluid has also been suggested as a marker for periodontal disease and obesity, 
demonstrating increases in concentration in GCF and serum (267).  
 
5.5.5 Study limitations 
Due to limited volume of samples available not all assays were complete for all subjects 
and therefore sample sizes vary across tests. The control cohort used in this study were 
generally 10 years younger than the periodontal disease cohort, work presented in 
Chapter 3 suggested age does not influence the variables measured in this study, apart 
from salivary RBP concentration. The data may also be affected by a lack of flow rate 
data for the periodontal disease cohort, and not having longer follow-up samples. A 
larger sample size might be required to truly assess differences in salivary RBP between 




Chapter 6 Interactions between the pathobiont; P. gingivalis, 
salivary haptocorrin, and vitamin B12 
 
6.1 Rationale 
Work presented in Chapter 5 demonstrated a lower concentration of salivary haptocorrin 
in a periodontal disease cohort prior to treatment, compared to a ten-week post treatment 
follow-up. Both sample points (before and after treatment) demonstrated lower salivary 
haptocorrin concentrations compared to a periodontally healthy cohort. Immunoblot data 
indicated the reduced concentrations may be a consequence of proteolytic activity, with 
observed reduced band intensity and band laddering. 
 
Porphyromonas gingivalis is a common commensal constituent of the oral microbiome 
with a strong association to periodontal disease. Although P. gingivalis has been isolated 
from numerous sites in the oral cavity, it is particularly enriched in plaque adjacent to 
inflamed sites (268). Key virulence factors of P. gingivalis, responsible for destruction of 
the dental supportive tissues and dysregulation of the immune response in the 
periodontium are a group of cysteine proteases termed ‘gingipains’ (189). Gingipains 
include two arginine- specific proteases RgpA and RgpB, and a lysine- specific gingipain 
Kgp, which can be secreted or membrane associated (269). The gingipains have been 
demonstrated to be important attributes for P. gingivalis to thrive in the subgingival 
environment including colonisation, immune evasion, and nutrient acquisition (270). 
 
It is becoming increasingly apparent that the nutritional requirement of vitamin B12 is not 
limited to higher kingdom organisms, numerous microbes lacking the complete 
machinery for de novo biosynthesis are also dependent on exogenous sources (271). 
Furthermore, the functional effects of vitamin B12 in microbes are far more diverse with 
the discovery of B12-riboswitches, which are ligand dependent regulators of transcription 
(272). Therefore; a host factor which sequesters vitamin B12 may have an important 
innate immune function. 
 
6.2 Aims 
To investigate interactions between the keystone species Porphyromonas gingivalis, 





6.3.1 Culture maintenance 
Porphyromonas gingivalis wild-type strain W50, and two isogenic Arg-, Lys-gingipain 
deletion knock-outs strains; E8 (RgpA/B) and K1A (Kgp) (kindly made available by 
Professor J. Naglik, Centre for Host-Microbiome Interactions) were maintained on 
Fastidious Anaerobic Agar (FAA) (Lab M, Heywood, U.K.), supplemented with 5% v/v 
defibrinated horse blood (E&O Laboratories Ltd, Bonnybridge, Scotland), at 37C in a 
Whitley MG1000 anaerobic workstation (Don Whitley Scientific Ltd, Bingley, U.K.), with 
an atmosphere of 80% nitrogen, 10% carbon dioxide, and 10% hydrogen.  
 
Streptococcus mutans NCTC 10449T (kindly made available by Steven Gilbert, Centre 
for Host-Microbiome Interactions) was maintained on Brain Heart Infusion agar (BHI) 
(Lab M, Heywood, U.K.) in the same anaerobic environment described for P. gingivalis. 
 
6.3.2 Preparation of liquid cultures, and culture supernatants  
Pre-reduced BHI broth supplemented with 5mg/mL haemin (Sigma-Aldrich, St. Louis, 
MI, U.S.A), was inoculated with P. gingivalis W50, E8 K1A, or S. mutans NCTC 10449T, 
and incubated in anaerobic conditions for 48 hours. The OD600 was measured and 
cultures normalised to an absorbance of 1 with media. Cultures were centrifuged at 
13,000g for 10 minutes to pellet bacteria. Supernatant was divided into aliquots and 
stored at -80C until use. Pellets were resuspended in the same volume of fresh media, 
prior to division into aliquots and storage at -80C. 
 
6.3.3 Investigating the interaction of oral pathobionts with haptocorrin 
An aliquot of each culture supernatant was heated to 100C for 15 minutes (referred to 
as pre-boiled supernatant). Recombinant haptocorrin (10ng/mL) (Abcam, Cambridge 
U.K.) was incubated with P. gingivalis W50 and S.mutans NCTC 10449T culture 
supernatants, or supernatant free media for 1 hour at either 37C or 4C (all 
combinations can be seen in Figure 6-2). Assay samples were then heated to 100C for 
2 minutes in the presence of NuPAGE LDS sample buffer (ThermoFisher, Waltham, MA, 
U.S.A.), and 1,4-Dithiothreitol (DTT) to halt the reaction. Samples were analysed by 
SDS-PAGE electrophoresis, western blot, and immunoprobed for haptocorrin (the full 
details of which can be found in Chapter 2). 
 
6.3.4 Influence of titrating P. gingivalis supernatant on interaction with haptocorrin 
Ten-fold dilution series were generated with P. gingivalis W50 culture supernatant and 
resuspended pellet, diluted with culture free media. This generated 11 dilutions ranging 
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from 100% - 0% v/v culture component. Recombinant haptocorrin was added to each 
dilution at a concentration 10ng/mL. The series was incubated at 37C for 1 hour. Assay 
samples were then heated to 100C for 2 minutes in the presence of NuPAGE LDS 
sample buffer and 1,4-Dithiothreitol (DTT) to halt the reaction. Samples were analysed 
by SDS-PAGE electrophoresis, western blot, and immunoprobed for haptocorrin (the full 
details of which can be found in Chapter 2). 
 
6.3.5 P. gingivalis gingipain knock-out strains and interactions with haptocorrin 
As described above, aliquots of culture supernatants from P. gingivalis wild-type parent 
strain W50, and two isogenic Arg-, Lys-gingipain knock-out strains; E8 and K1A were 
incubated for 1 hour at 37C. Assay samples were then heated to 100C for 2 minutes 
in the presence of NuPAGE LDS sample buffer and 1,4-Dithiothreitol (DTT) to halt the 
reaction. Samples were analysed by SDS-PAGE electrophoresis, western blot, and 
immunoprobed for haptocorrin (the full details of which can be found in Chapter 2). 
 
6.3.6 Interaction between gingipains and native salivary haptocorrin 
Ethical approval for human saliva collection was obtained from the Biomedical Sciences, 
Medicine, Dentistry and Natural and Mathematical Sciences subcommittee of the King’s 
College London Research Ethics Committee (Reference: BDM/14/15-61). Whole mouth 
saliva was collected from two healthy individuals by expectoration into sterile universal 
tubes. Samples were divided into aliquots and centrifuged at 13,500rpm for 5 minutes at 
45C, salivary pellets were discarded. Each aliquot was divided into 4, each divided 
aliquot was then diluted 1:1 v/v with (a) culture free media, (b) W50 culture supernatant, 
(c) E8 culture supernatant or (d) K1A culture supernatant for 1 hour at 37C. Assay 
samples were then heated to 100C for 2 minutes in the presence of NuPAGE LDS 
sample buffer and 1,4-Dithiothreitol (DTT) to halt the reaction. Samples were analysed 
by SDS-PAGE electrophoresis, western blot, and immunoprobed for haptocorrin (the full 
details of which can be found in Chapter 2). 
 
6.3.7 Vitamin B12 dependent P. gingivalis growth  
P. gingivalis strain W50 culture was collected by loop and washed three times by 
suspended in phosphate-buffered saline (PBS), and centrifugation at 2000g for 3 
minutes. The pellet was finally resuspended in pre-reduced defined medium which 
excluded vitamin B12 analogues and downstream nutrients of the vitamin B12 dependent 
pathways (See Appendix 16 for composition). Medium was supplemented with 5mg/mL 
Haemin, and 2.5mg/mL sodium-thioglycolate (Sigma-Aldrich, St. Louis, MI, U.S.A). 
Culture was normalised to by absorbance at 600nm to 0.1. Cultures were loaded onto 
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a 96-well microtiter plate in triplicate and supplemented with either adenosylcobalamin 
(Sigma-Aldrich, St. Louis, MI, U.S.A) or methylcobalamin (Sigma-Aldrich, St. Louis, MI, 
U.S.A) to final concentrations of 1000pg/mL, 100pg/mL, or 0pg/mL (please refer to 
Figure 6-1). Additionally, 1000pg/mL concentration wells were supplemented with 
recombinant haptocorrin (final concentration of 1µg/mL). Plates were placed into an 
anaerobic chamber and sealed before loading onto iEMS 96-well microplate reader 
(MTX Lab Systems LLC Bradenton, FL, U.S.A.), incubated at 37C, with gentle agitation, 




Figure 6-2 is a representative immunoblot probed for haptocorrin, and composite graph. 
Culture supernatant from (i), P. gingivalis strain W50 and (ii) S. mutans strain NCTC 
10449T were incubated with recombinant haptocorrin under various conditions 
demonstrated in the figure table. Haptocorrin was not detectible via this method when 
incubated at 37C for 1 hour with P. gingivalis culture supernatant, this was however, not 
the same for S. mutans (as demonstrated in lane 2). Haptocorrin was detectable by 
immunoblot if the supernatant was pre-boiled prior to incubation, or if the incubation was 
undertaken at 4C graphical data in Figure 6-2 is band intensity data from three repeated 
immunoblots, normalised to lane 4, haptocorrin alone. Data is presented as means and 
standard deviations. Statistical analysis consisted of two-way ANOVA and Sidak’s 
multiple comparisons test. Please note values from lane one (protein standard) were 
excluded from the graphical representation. 
 
Figure 6-1 Chemical structures of vitamin B12 species 




The influence of P. gingivalis culture supernatant on the band intensity of haptocorrin is 
titratable as demonstrated in Figure 6-3 (i), when incubated for one hour at 37C, with 
reductions in culture percentage. Furthermore, a similar effect was observed when 
haptocorrin was incubated with resuspended P. gingivalis pellet. Data presented 
graphically are normalised to control (0% of P. gingivalis culture) means and standard 
deviations of three repeats are presented.  
Figure 6-2 Haptocorrin incubated with P. gingivalis and S. mutans culture 
supernatants 
Immunoblots probed for haptocorrin, representative of three repeats. Band intensity normalised 
to lane four, means and corresponding standard deviations are presented. (i) P. gingivalis 
strain W50 and (ii) S. mutans culture supernatants inoculated with recombinant haptocorrin 
and incubated for 1 hour under various conditions. ( = p <0.05), ( = p <0.001), ( = p 
<0.0001) 
 
Haptocorrin + + +   +  - - - - 
Bacterial supernatant  + - -   +  + - - + 
Pre-boiled bacterial supernatant - + -   -  - + - - 
Supernatant free media  - - +   -  - - + - 
37°C incubation + + +   -  + + + - 
4°C incubation - - -   +  - - - + 
Standard                                + 
        
 (i) 
(ii) 



































































P. gingivalis expresses three cysteine proteases, RgpA/B and Kgp. Two knockout strains 
E8 (RgpA/B deletion) and K1A (Kgp deletion) were cultured as described earlier. Figure 
6-4 demonstrates a significantly lower band intensity (90%) in the wild type strain (lane 
7) when compared to control (lane 3). Incubation of recombinant haptocorrin with the 
arginine-specific gingipain knock-out (lane 9) demonstrated a lower band intensity of 
45%, compared to the lysine-specific gingipain knock-out (K1A) which demonstrated a 
lower band intensity of 75%. 
Figure 6-3 Haptocorrin incubated with titrations of P. gingivalis supernatant 
and biomass 
Immunoblots probed for haptocorrin, representative of three repeats. Band intensity 
normalised to 0% of P. gingivalis culture control. Means and corresponding standard 
deviations are presented. P. gingivalis strain W50 culture separated into (i) supernatant and 







































Figure 6-5 is an immunoblot probed for haptocorrin. Saliva from two periodontally healthy 
individuals was incubated with culture free medium as a control (lanes 1 & 5), and culture 
supernatant from either wild-type W50 (lanes 2 & 6), RgpA/B mutant (lanes 3 & 7), or 
KgpA mutant (lanes 4 & 8). Graphically, data are presented individually as a percentage 
of the control band. No band was detectable post incubation with the supernatant of 
Figure 6-4 Haptocorrin incubated with P. gingivalis strain W50, and isogenic 
gingipain mutants E8 (RgpA/B), and K1A (Kgp) supernatants 
Immunoblots probed for haptocorrin, representative of three repeats. Band intensity normalised 
to lane three, means and corresponding standard deviations are presented. Statistical analysis 
was undertaken by one-way ANOVA and Dunnett’s multiple comparisons test. (1) Media, (2) 
Haptocorrin standard, (3) Media + haptocorrin, (4) W50 (wt) supernatant, (5) E8 supernatant 
(RgpA/B mutant), (6) K1A supernatant (Kgp mutant), (7) W50 (wt) supernatant + haptocorrin, 
(8) E8 supernatant + haptocorrin, (9) K1A supernatant + haptocorrin. ( = p <0.0001) 
 





























1      2       3     4      5      6     7     8 
Figure 6-5 Salivary haptocorrin incubated with P. gingivalis strain W50, and 
isogenic gingipain mutants E8 (RgpA/B), and K1A (Kgp) supernatants 
Immunoblot probed for haptocorrin. Band intensity normalised to unstimulated whole mouth 
saliva (lanes 1 & 5). (1 & 5) Whole mouth saliva, incubated with W50 (wt) (2 & 6), E8 (RgpA/B) 







































strain W50, band intensity was greatly reduced in both participants when incubated with 
strain E8, however only by 5% when incubated with K1A. 
 
Figure 6-6 demonstrates P. gingivalis growth was limited in defined medium which lacked 
cobalamin analogues and nutrients down stream of cobalamin dependent processes 
such as methionine. Supplementation of the medium with physiologically active 
cobalamin analogue; adenosylcobalamin, facilitates growth and was dose dependent. 
The positive effect of adenosylcobalamin was attenuated when the medium was further 
supplemented with recombinant haptocorrin.  
 
 
A similar positive effect on P. gingivalis growth was observed when repeated with 
methylcobalamin (Figure 6-7), another physiologically active cobalamin analogue. P. 
gingivalis growth with methylcobalamin concentration of 1000pg/mL was also limited with 
the addition of haptocorrin.  
 
Figure 6-6 Adenosylcobalamin dependent P. gingivalis growth 
Mean cell density of P. gingivalis cultured in defined medium supplemented with titrated 
concentrations of adenosylcobalamin and haptocorrin. 
 




















6.5.1 Gingipain mediated degradation of haptocorrin 
The preparatory work presented in this chapter suggests a secreted component of P. 
gingivalis reduces the detectability of haptocorrin by immunoblot, which does not occur 
when the process is repeated with S. mutans. Boiling of the supernatant prevented this 
process or incubating at 4C reduced the severity of detection loss. The extensively 
researched cysteine proteases of P. gingivalis, gingipains, are a likely candidate for 
haptocorrin degradation due to their promiscuity and association with periodontal 
disease (273). P. gingivalis contains two gene loci rgpA and rgpB which encode the Arg-
X specific gingipains and kpg which encodes the Lys-X gingipain (274). The amino acid 
sequence of haptocorrin was published in the late 1980s and demonstrates an 
abundance of arginine, and lysine residues that could be cleavage sites for gingipains 
(275). 
 
Figure 6-7 Methylcobalamin dependent P. gingivalis growth 
Mean cell density of P. gingivalis cultured in defined medium supplemented with titrated 
concentrations of methylcobalamin and haptocorrin. 
 


















In this study P. gingivalis strain W50 and two isogenic mutant strains E8 (Knock-out 
mutant for the Arg-X gingipains), and strain K1A (knock-out mutant for the Lys-X 
gingipain) were used (276). When assayed with recombinant haptocorrin, knock-out of 
the Arg-X specific gingipains had the greatest influence on reducing signal loss 
compared to knock-out of the Lys-X specific gingipain. Conversely, when repeated with 
native salivary haptocorrin, knock-out of the Lys-X gingipain had the greatest influence. 
Native haptocorrin is an extensively glycosylated glycoprotein with N- linked 
carbohydrates contributing approximately 25% of its molecular weight (277). The 
recombinant protein used in this study was wheat germ in origin and therefore may not 
contain the extensive glycosylation of the native haptocorrin (278). This difference may 
explain the reduced influence of the Arg-X gingipains on native salivary haptocorrin 
signal loss. To determine if this was a factor, deglycosylation experiments could be 
attempted. In vitro this may be performed by other bacteria within a biofilm system.  
 
The in vitro assays presented in this chapter suggest gingipains, specifically the Lys-X 
specific gingipain of P. gingivalis may, at least in part, contribute to the lower 
concentration of salivary haptocorrin observed in the periodontal cohort presented in 
Chapter 5. The oral environment is far more complex, than this model system. 
Periodontal disease associated proteases are not only microbial in origin, host derived 
matrix metalloproteases (MMPs) are responsible for collagen and extracellular matrix 
(ECM) degradation (279). MMP concentrations are typically tightly regulated in 
accordance to concentrations of their inhibitors; tissue inhibitors of metalloproteases 
(TIMPS) (280). 
 
6.5.2 The influence of vitamin B12 and haptocorrin on P. gingivalis growth 
Biosynthesis of vitamin B12 is a complex 30-enzyme-mediated step process and is 
restricted to a relatively small number of microbial species (281, 282). Porphyromonas 
gingivalis lacks 5- aminolaevulinic-acid dehydrogenase and porphobilinogen deaminase 
which are two enzymes essential for the early biosynthesis pathway; however, significant 
components of the later pathway are conserved (197). The data presented in this chapter 
suggest P. gingivalis growth is vitamin B12 dependent, the two cobalamin analogues used 
in this study adenosyl-, and methyl-cobalamin are the two physiologically active forms in 
humans. Both supported P. gingivalis growth in a dose dependent manner.  
 
Haptocorrin is capable of binding a number of cobalamin analogues, which may render 
the vitamin inaccessible (283). The data presented in this chapter indicate that P. 
gingivalis growth was limited with the addition of haptocorrin, it is likely this was due to 
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sequestration of the cobalamin analogues and therefore growth was limited. Haptocorrin 
was not degraded by the gingipains in the latter experiments, this could be a result of 
reduced gingipain expression as a consequence of impaired metabolic activity, or 
perhaps reduced proteolysis due to a conformational change in the binding protein when 
bound to its ligand. Interestingly, haptocorrin is a constituent of a number of exocrine 
secretions including saliva, tears, and breast milk, as well as being a component of 
neutrophil secretory granules (91, 92). Due to the nature and localisation of haptocorrin 
expression, it is often suggested to facilitate an innate immune function by sequestering 
vitamin B12 and therefore limiting microbial growth, however this hypothesis is poorly 
substantiated in the literature (284).  
 
6.5.3 Future considerations 
To complete this work, it should be confirmed that P. gingivalis, and ultimately gingipains 
are detectible in the saliva sample of the periodontal disease cohort. A proteomics 






Chapter 7 General discussion 
Although the functions of vitamin D-binding protein (DBP), haptocorrin (Hc), and retinol-
binding protein (RBP) have been researched intensively in blood, their extra-circulatory 
functions have been comparatively neglected (91, 121, 285-287). All three of these 
proteins are present in a number of exocrine secretions, including saliva. There is a lack 
of literature aimed at understanding the function of these proteins within the context of 
saliva. The vital nature of vitamins for health, homeostasis and development drives a 
need for clear understanding of their assimilation pathways. The vitamin B12-binding 
protein; haptocorrin, is considered to have an important role in chaperoning dietary 
vitamin B12 through the acidic milieu of the stomach (79). Work presented in this thesis 
indicates salivary vitamin-binding proteins enter the oral cavity from different routes and 
regulation of their expression may differ from circulatory counterparts. High 
concentrations of all three proteins are present at resting salivary flow and increase with 
mastication stimulation, therefore could play a role in dietary vitamin assimilation. 
Additionally, salivary vitamin binding proteins may contribute to oral homeostasis, be it 
either sequestration of vitamins required by the oral microbiota, or alternative functions.  
 
7.1.1 The biomarker potential of salivary vitamin-binding proteins  
The ability to non-invasively monitor systemic health biochemically is of great benefit to 
health professionals. Saliva offers a less-invasive, easily accessible alternative to blood 
(288). Attempts have been made to quantify vitamin concentration directly in saliva to 
limited success for vitamins D and B12 (289). The intention of this study was to assess 
the potential of salivary vitamin-binding proteins as surrogate markers of vitamin status. 
Data presented in Chapter 3 suggested that circulatory concentrations of DBP, Hc, and 
RBP displayed positive relationships to commonly applied clinical markers of vitamin D, 
B12, and A status, respectively. However, this was not the case for salivary vitamin-
binding protein concentration or outputs. The disparity in trend between vitamin-binding 
protein concentration across the two biofluids questions the origin of these proteins in 
saliva and what regulates their expression. Data presented in Chapter 5 indicated that 
salivary haptocorrin concentration was lower in periodontal disease patients prior to 
treatment and increasing significantly in those who responded to treatment. Although 
further work should be undertaken, haptocorrin could be suggestive of periodontal 




7.1.2 Vitamin-binding proteins in the oral cavity, considerations for vitamin 
assimilation 
Saliva contributes to the digestive process in a number of ways, firstly the softening of 
hard foods in the oral cavity, and aggregation of food particles generated by mastication. 
Saliva also acts to lubricate the food bolus as it transits into the stomach, preventing 
abrasion of the mucosal tissues (290). At a biochemical level, amylase is the most 
abundant salivary protein and considered to contribute to starch digestion, or at least 
clearance from the oral cavity post mastication (291). Salivary haptocorrin is considered 
to bind cobalamin reduced from the food matrix, which would most likely occur during 
chemical degradation of food in the stomach (214). The binding of haptocorrin to 
cobalamin and its analogues occurs at neutral pH, but the binding affinity increases 
significantly at lower pH (93). Indeed, the work presented in Chapter 4 demonstrated that 
all three of the binding proteins studied increased in output with mastication stimulation 
of salivary flow and therefore there would be an abundance in the stomach during 
digestion. The binding affinity of DBP for vitamin D metabolites however increases with 
alkalinity (292); furthermore, the lipophilic nature of vitamin D leads to incorporation into 
mixed micelles in the lipid fraction of a meal which may limit access by DBP (293). These 
factors suggest DBP does not have a role in gastric transit of vitamin D, however the 
gastrointestinal luminal environment neutralises in the duodenum where speculatively it 
could transfer to DBP. The multi-ligand receptor megalin, is expressed by the intestinal 
epithelium, there is evidence to suggest megalin mediates endocytosis of DBP-vitamin 
D complexes which could be a novel absorption route for dietary vitamin D (34). A similar 
argument could be made for RBP, which displays optimal binding at pH 7.4; vitamin A 
metabolites are also lipophilic (294). 
 
Chapter 5 reported a lower salivary concentration of haptocorrin in a cohort of periodontal 
disease patients, this difference was not reflected in systemic vitamin B12 status, as 
determined by serum concentrations of total-vitamin B12. This could be rationalised in a 
number of ways. Firstly, the samples analysed from the disease cohort were resting 
whole mouth saliva samples. Chapter 4 showed that stimulation of salivary flow by 
mastication increased salivary output of haptocorrin during digestion. This increase in 
output may be sufficient to maintain assimilation. Haptocorrin present in the oral cavity 
at resting salivary flow rate may be retained in the oral cavity for longer, and therefore 
open to proteolysis as demonstrated in Chapter 6. Additionally; haptocorrin is expressed 





7.1.3 The influence of periodontal disease on vitamin status 
Relationships between micronutrient deficiencies and periodontal disease have been 
suggested in the literature. Inadequate intake of the antioxidant vitamins (Including 
vitamin A) correlates significantly with periodontal disease severity (265). Work 
presented here demonstrated no significant difference in serum retinol status between 
patients or healthy controls, however there was a trend to a lower retinol concentration 
in the pre-treatment patient group. Both vitamin D, and B12 have been shown to correlate 
negatively with periodontal disease in the literature (55, 107). The data presented in 
Chapter 5 does not show a clear trend in status of either vitamin, before or after treatment 
for periodontal disease. Vitamin D status was no lower in the periodontal disease cohort 
than healthy controls. Vitamin B12 status was surprisingly higher in the periodontal 
disease cohort than healthy controls, which was inverse to the trend in salivary 
haptocorrin concentration. The difference in vitamin B12 status may be a consequence 
of different dietary behaviours between disease and control groups, however there is no 
literature to support this. 
 
7.1.4 Is vitamin D-binding a driver of oral homeostasis? 
Vitamin D-binding protein is highly multifunctional. Data presented in Chapter 3 and 
Chapter 4 demonstrated that DBP was highly abundant in saliva, and suggested it 
originated, at least partly, from gingival crevicular fluid. This supports published data 
which shows DBP is highly abundant in GCF (199). In addition to binding vitamin D 
metabolites, DBP is also a scavenger of G-actin, an activator of macrophages (by 
enhancing phagocytosis), and enhancing chemotactic activity of complement system 
components (286).  
 
7.1.5 Haptocorrin as a potential modulator of polymicrobial community ecology 
With the discovery of vitamin B12-dependent riboswitches, it is becoming increasingly 
clear that vitamin B12 and its analogues are widely required by microbes for transcription 
regulation as well as enzymatic cofactors (295, 296). Indeed, the recently published 
expansion of the Human Microbiome Project highlighted the enrichment of vitamin B12 
biosynthesis genes in the oral microbiome, the authors note the potential influence 
salivary haptocorrin may have on cobalamin bioavailability (297). The highly selective 
assimilation vitamin B12 assimilation pathway of humans for physiologically active 
cobalamin analogues is facilitated by intrinsic factor, and 80% of alternative analogues 
are converted to microbially-active forms by the gut microbiota (93, 298). Recent data 
has illustrated that riboswitches are able to discriminate between cobalamin analogues 
with adenosylcobalamin, methylcobalamin, and aquocobalamin acting as ligands for 
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different riboswitches (299). Data presented in Chapter 6 complement published work 
which demonstrated cobalamin (in this case methylcobalamin, and adenosylcobalamin) 
was exogenously required by P. gingivalis for growth, but also suggested that haptocorrin 
can inhibit P. gingivalis growth, presumably by sequestration of cobalamin (197). 
Heterogeneity of cobalamin biosynthesis in the bacterial kingdom is now considered to 
induce complex syntrophic relationships in polymicrobial communities, driving 
spatiotemporal structure (300). Numerous redundant bacterial vitamin B12 receptors 
have been identified, and are suggested to offer competitive advantage in polymicrobial 
communities (301). Haptocorrin is a constituent of a number of exocrine products, 
secreted onto mucosal surfaces, along with the iron chelating protein lactoferrin, both 
proteins are secreted by neutrophils (91, 226, 302). Gaining a clearer understanding of 
the modulatory ability of cobalamin on biofilm composition or dysbiosis may have 
significant clinical applications for periodontal disease.  
 
7.1.6 Summary 
The first objective of this thesis was to understand the relationship between salivary, and 
serum vitamin-binding protein concentrations with their corresponding vitamin ligands. 
The work presented in Chapter 3 showed that the concentrations of vitamin-binding 
proteins in saliva did not correlate with vitamin status. Furthermore, the degree of 
correlation between concentrations of vitamin-binding proteins across the two biofluids 
(saliva and serum) was greatly different between proteins, suggesting sources of the 
proteins in saliva varied. 
 
The second objective of this thesis was to gain a clearer understanding of the origins of 
the three vitamin-binding proteins in saliva which was presented in Chapter 4. The 
salivary concentrations of the three proteins varied between protein and indeed between 
individual when salivary flow was stimulated by mastication, this suggested that the 
sources varied. Inter-personal variation may suggest that oral health, possibly gingival 
health influences the salivary concentration of vitamin-binding proteins. All three of the 
proteins increased in output when salivary flow was upregulated by mastication, and 
therefore would be present during the oral processing of food. Saliva secretions were 
collected from the parotid glands, non-parotid glandular secretion, as well as whole 
mouth, these data suggested that vitamin D-binding protein was largely non-parotid in 
origin, and possibly a contaminant from the gingival crevicular fluid. Haptocorrin and 
retinol-binding protein were detectable in all salivary types and may be expressed by 




Periodontal disease is associated with a number of micronutrient deficiencies, the most 
commonly reported being vitamin D deficiency (62, 247, 303). The objective of Chapter 
5 was to assess the influence of periodontal disease on salivary vitamin-binding protein 
concentration, and ultimately vitamin status. Interestingly, vitamin D and A status did not 
differ in a periodontal disease patient cohort after standard treatment and were not 
significantly different from a healthy cohort. No difference was identified in retinol-binding 
protein concentration before or after treatment, or when compared to a health cohort. 
Vitamin D-binding protein concentration was lower in the disease cohort after treatment, 
this suggested that the positive effect of treatment on the periodontium led to reduced 
contamination of gingival crevicular fluid which has a high concentration of DBP. Salivary 
haptocorrin was higher in concentration post treatment, and concentrations of 
haptocorrin were significantly lower in both disease cohort samples when compared to 
healthy controls. Immunoblot provided evidence for degradation of haptocorrin prior to 
treatment. The patients that responded well to treatment had a significant increase in 
haptocorrin concertation post treatment, thus suggesting active periodontal disease 
reduces salivary haptocorrin concentration. Conversely, vitamin B12 status behaved 
inversely to haptocorrin, in being significantly higher in the disease cohort compared to 
controls. 
 
The final aim of this thesis was to gain a clearer understand the interactions between 
salivary haptocorrin, and P. gingivalis. Data presented in Chapter 6 suggested that P. 
gingivalis degraded haptocorrin in vitro, which could, at least in part, be attributed to the 
secreted cysteine gingipain proteases. As with many microbial species, P. gingivalis 
required exogenous vitamin B12 to metabolically function (197). Chapter 6 demonstrated 
P. gingivalis growth was dependent on analogues of vitamin B12 being present within the 
growth media, and this growth was attenuated when the media was supplemented with 
haptocorrin. It is possible that P. gingivalis was not capable of secreting gingipains when 
metabolically limited, and therefore haptocorrin expressed a bacteriostatic effect on the 
bacterium. 
 
7.1.7 Future work 
The work presented in this thesis could be continued in a number of ways. Firstly, more 
work could be done to understand the suitability of salivary haptocorrin concentration to 
be used as a prognostic biomarker for the outcome of periodontal disease treatment. 




Vitamin D-binding protein is present at high concentrations in serum, saliva and 
particularly, gingival crevicular fluid (199). The multifunctionality of this protein is 
becoming increasingly clear, and it exerts influence in a number of ways beyond 
transport of vitamin D metabolites (286). Some of these functions, such as enhancement 
of C5a mediated leukocyte chemotaxis, and actin monomer sequestration, could support 
homeostasis of the periodontium (40, 260, 261). The high DBP concentration in GCF, 
and the diverse functions make it an attractive target for future work in this regard. 
 
The data presented in this thesis compliment a number of publications which suggest 
the vitamin B12 can modulate microbial growth, and untimely polymicrobial community 
structure. A potentially interesting avenue of future work would be to gain a greater 
understanding of microbial syntrophy in relation to analogues of vitamin B12 and the 
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Participant ID Gender Age  Pre-weight  Post-weight  Duration  Flow rate  
      (g) (g) (minutes) (g/min) 
1 F 26 15.47 20.36 10 0.49 
2 M 21 15.46 21.71 10 0.63 
3 F 28 15.78 23.60 10 0.78 
4 M 41 15.51 20.30 10 0.48 
5 M 25 15.30 22.40 10 0.71 
6 M 26 15.04 18.46 10 0.34 
7 F 26 15.41 19.43 10 0.40 
8 F 34 15.04 20.28 10 0.52 
9 M 23 15.70 18.41 10 0.27 
10 F 34 15.70 21.39 10 0.57 
11 M 19 15.21 18.73 10 0.35 
12 M 43 15.53 19.10 10 0.36 
13 F 22 15.31 16.48 10 0.12 
14 M 56 15.26 19.05 10 0.38 
 
Appendix 1 Raw participant demographic and salivary flow rate data (Chapter 3). 
Participant ID Serum [25-OH-D] Salivary [DBP] Salivary DBP output  Serum [DBP]  
  (nmol/L) (ng/mL) (ng/min) (μg/mL) 
1 46 155.21 75.84 273.62 
2 23 99.97 62.44 236.95 
3 68 674.57 527.15 631.71 
4 20 331.24 158.55 443.30 
5 55 165.84 117.67 456.16 
6 79 186.63 63.83 443.94 
7 24 116.32 46.76 299.97 
8 46 141.71 74.26 331.87 
9 68 181.56 49.20 250.29 
10 49 866.16 492.84 380.92 
11 10 41.71 14.68 153.62 
12 36 420.60 150.16 327.11 
13 7 140.13 16.39 341.40 
14 35 250.29 94.86 261.87 
 
Appendix 2 Raw serum 25-OH-D and salivary vitamin D-binding protein concentration 





Participant ID Serum [total- B12] Salivary [Hc] Salivary Hc output  Serum [Hc]  
  (ng/L) (pg/mL) (pg/min) (pg/mL) 
1 164 19.34 51.51 252.51 
2 334 11.83 15.95 110.12 
3 157 76.83 98.66 1343.04 
4 163 34.53 38.82 540.77 
5 228 37.65 40.30 599.81 
6 347 25.93 30.11 377.54 
7 350 19.89 89.85 262.93 
8 194 20.07 53.42 266.40 
9 195 10.00 14.45 75.39 
10 316 34.72 111.36 544.24 
11 189 42.77 33.44 697.05 
12 326 52.48 16.96 881.12 
13 298 37.83 11.52 603.28 
14 454 19.89 83.39 262.93 
 
Appendix 3 Raw serum total-vitamin B12 and salivary haptocorrin concentration and 
output data (Chapter 3) 
Participant ID Serum [retinol] Salivary [RBP] Salivary RBP output  Serum [RBP]  
  (μmol/L)  (g/mL) (μg/min)  (g/mL) 
1 2.10 1.50 0.73 98.40 
2 1.44 1.67 1.04 80.19 
3 2.10 1.44 0.35 88.88 
4 2.26 1.56 1.22 97.56 
5 2.19 1.65 0.79 93.88 
6 1.89 1.65 1.17 79.77 
7 1.52 1.64 0.56 92.42 
8 2.07 1.60 0.64 97.08 
9 2.69 1.51 0.79 103.12 
10 2.54 1.54 0.42 99.16 
11 1.95 1.64 0.93 82.55 
12 2.68 0.84 0.30 102.99 
13 1.63 0.95 0.34 95.06 
14 1.99 1.02 0.12 85.75 
 
Appendix 4 Raw serum retinol and salivary retinol-binding protein concentration 




  R2 p 
Resting salivary flow rate (mL/min) <0.01 0.99 
   
Serum [25-OH-D] (nmol/L) <0.01 0.96 
Salivary [DBP] (ng/mL) <0.01 0.81 
Salivary DBP output (ng/min) 0.04 0.50 
Serum [DBP] (µg/mL) 0.01 0.75 
   
Serum [total-B12] (ng/L) 0.17 0.15 
Salivary [Hc] (pg/mL) <0.01 0.86 
Salivary Hc output (pg/min) 0.11 0.25 
Serum [Hc] (pg/mL) <0.01 0.87 
   
Serum [retinol] (µmol/L) 0.01 0.74 
Salivary [RBP] (µg/mL) 0.61 <0.01 
Salivary RBP output (µg/min) 0.44 0.01 
Serum [RBP] (µg/mL) <0.01 0.99 
 
Appendix 5 Influence of age on serum vitamin concentration and serum/ salivary 























































































































































































































































































































































































































































































































































































































































































































































































































































































Female vs. male participants p 
Resting flow rate (mL/min) 0.98 
Stimulated flow rate (mL/min) 0.26 
  
Resting [total-protein] (mg/mL) 0.27 
Resting total-protein output (mg/min) 0.08 
Stimulated [total-protein] (mg/mL) 0.60 
Stimulated total-protein output (mg/min) 0.31 
  
Resting [DBP] (ng/mL) 0.34 
Resting DBP output (ng/min) 0.55 
Stimulated [DBP] (ng/mL) 0.55 
Stimulated DBP output (ng/min) 0.94 
  
Resting [Hc] (pg/mL) 0.27 
Resting Hc output (pg/min) 0.90 
Stimulated [Hc] (pg/mL) 0.60 
Stimulated Hc output (pg/min) 0.72 
  
Resting [RBP] (µg/mL) 0.02 
Resting RBP output (µg/min) 0.68 
Stimulated [RBP] (µg/mL) 0.16 
Stimulated RBP output (µg/min) 0.41 
Tucky's multiple comparisons test   
 
Appendix 7 Influence of gender of salivary flow rate, total protein 
concentration, and salivary vitamin-binding protein concentration and 







Participant ID Salivary [DBP] Salivary DBP output  
 (ng/mL) (ng/min) 
  Resting Stimulated Resting Stimulated 
1 34.32 26.95 31.30 89.58 
2 134.25 133.08 70.35 102.20 
3 45.95 59.53 40.99 90.49 
4 42.76 31.73 29.76 78.30 
5 51.15 106.76 23.73 89.04 
6 24.62 19.73 32.64 50.24 
7 42.23 26.63 28.80 48.15 
8 94.98 39.16 50.59 124.44 
9 83.73 70.36 44.38 75.57 
10 92.33 38.09 40.44 73.83 
 
Appendix 8 Raw salivary DBP concentration and output data (Chapter 4) 
Participant ID Salivary [Hc] Salivary Hc output  
 (pg/mL) (pg/min) 
  Resting Stimulated Resting Stimulated 
1 46.41 30.01 42.33 99.74 
2 54.77 44.70 28.70 34.33 
3 48.05 35.97 42.86 54.68 
4 32.47 13.97 22.60 34.49 
5 40.52 21.64 18.80 18.05 
6 46.94 43.21 62.24 110.00 
7 35.75 28.52 24.38 51.56 
8 40.82 4.20 21.74 13.36 
9 62.89 28.59 33.33 30.71 
10 70.72 39.78 30.98 77.09 
 





Participant ID Salivary [RBP] Salivary RBP output  
 (µg/mL) (µg/min) 
  Resting Stimulated Resting Stimulated 
1 1.35 1.45 1.23 4.81 
2 4.61 3.30 2.42 2.53 
3 1.44 2.02 1.28 3.07 
4 3.41 1.45 2.37 3.59 
5 1.38 2.75 0.64 2.30 
6 1.82 0.37 2.41 0.93 
7 0.07 0.19 0.05 0.35 
8 1.38 0.72 0.74 2.29 
9 1.55 0.86 0.82 0.92 
10 3.78 3.06 1.66 5.94 
 




  Participant A Participant B 
  Resting Stimulated Resting Stimulated 
Salivary flow rate (mL/min)         
Whole mouth 0.51 2.60 1.10 2.57 
Right Parotid 0.06 0.58 0.09 0.64 
Left Parotid 0.06 1.07 0.11 0.46 
Whole mouth (non-parotid) 0.22 0.60 0.51 1.11 
     
Salivary [total-protein] 
(mg/mL)     
Whole mouth 2.09 1.08 1.72 1.45 
Right Parotid 3.26 1.28 3.03 1.76 
Left Parotid 3.29 0.52 2.75 1.90 
Whole mouth (non-parotid) 1.00 0.90 1.09 0.99 
     
Salivary [DBP] (ng/mL)     
Whole mouth 190.31 109.77 135.49 158.15 
Right Parotid 54.37 17.83 116.64 33.18 
Left Parotid 55.54 18.56 84.34 28.06 
Whole mouth (non-parotid) 59.78 164.73 160.93 367.46 
     
Salivary [Hc] (pg/mL)     
Whole mouth 5.80 4.22 7.48 3.27 
Right Parotid 6.05 3.48 10.79 4.46 
Left Parotid 7.04 3.06 10.54 3.76 
Whole mouth (non-parotid) 1.12 4.45 5.59 3.17 
     
Salivary [Hc] (pg/mL)     
Whole mouth 2.52 2.75 1.21 2.19 
Right Parotid 1.09 6.88 1.50 0.41 
Left Parotid 1.30 0.27 1.33 0.26 
Whole mouth (non-parotid) 0.91 2.85 1.46 2.23 
To calculate rate of analyte output, multiply the analyte concentration by salivary flow rate 
Appendix 11 Raw salivary flow rate and vitamin-binding protein concentration 





Participant  Gender Age Smoking status* 
Response to 
treatment*2 
1 M 40 N Y 
2 F 58 Y Y 
3 F 52 Never Y 
4 F 43 Y Y 
5 M 52 Never Y 
6 F 42 Never Y 
7 F 38 N Y 
8 M 42 Never Y 
9 M 57 N Y 
10 M 38 Never Y 
11 F 50 N N 
12 F 35 Never Y 
13 F 37 N Y 
14 F 39 Y N 
15 M 60 N N 
16 F 42 N N 
17 F 55 N Y 
18 F 38 Y N 
19 M 51 Never Y 
20 F 41 Never Y 
21 M 23 Never Y 
22 M 55 N Y 
23 F 50 Y N 
24 F 36 Y Y 
25 F 50 Never N 
26 M 35 Y Y 
27 M 30 Y N 
28 M 49 Never Y 
29 F 37 Never Y 
30 M 49 N Y 
* Smoking status Y = current smoker, N = previous smoker, never = 
never smoked 
 
*2 Responsiveness to treatment (as defined in 5.3.3) Y – responsive, N – non-responsive 
Appendix 12 Raw patient demographic and smoking status data for a periodontal 





Participant  Serum [25-OH-D]  Serum [total-B12]  Serum [retinol]  
 (nmol/L) (ng/L) (µmol/L) 
  Before After Before After Before After 
1 20 20 338 339 - - 
2 44 26 319 397 2.40 1.65 
3 29 20 408 410 - - 
4 46 37 593 212 2.52 2.22 
5 73 20 397 212 - - 
6 26 30 434 617 2.70 2.31 
7 30 27 419 276 - - 
8 65 32 615 388 - - 
9 - - - - 0.97 0.92 
10 35 29 313 256 - - 
11 23 24 289 763 1.55 1.72 
12 25 58 740 406 - - 
13 52 54 395 316 1.25 2.03 
14 - - - - - - 
15 49 42 - - 2.40 1.81 
16 39 56 476 140 - - 
17 50 40 194 605 1.42 1.03 
18 28 20 507 597 - - 
19 20 72 630 302 0.52 1.59 
20 57 20 285 385 - - 
21 - - - - 1.11 0.96 
22 33 20 409 365 - - 
23 34 35 219 247 - - 
24 86 20 297 612 1.08 1.04 
25 22 34 688 689 - - 
26 25 20 323 357 - - 
27 - - - - - - 
28 40 29 682 145 - - 
29 - - - - - - 
30 - - - - - - 
Measurements before and after treatment (– denotes missing values). 
Appendix 13 Raw serum vitamin concentrations for a periodontal disease patient 





Participant  Salivary [DBP]  Salivary [Hc]  Serum [RBP]  
 (ng/mL) (pg/mL) (µg/mL) 
  Before After Before After Before After 
1 90.21 80.53 26.65 40.90 5.49 5.64 
2 25.26 15.24 5.51 24.12 1.80 1.68 
3 205.94 224.35 8.23 64.09 4.89 9.23 
4 35.96 19.91 12.11 32.69 0.87 0.69 
5 108.72 46.65 8.31 12.67 1.46 1.15 
6 192.35 174.81 6.72 8.25 4.54 5.47 
7 213.98 113.42 4.41 3.96 3.91 3.95 
8 31.49 19.57 24.12 25.53 2.87 1.65 
9 423.60 113.73 7.01 25.37 4.54 1.28 
10 46.06 46.65 20.74 21.43 2.32 4.38 
11 45.20 44.23 27.84 26.73 1.78 0.33 
12 15.66 13.88 5.66 12.20 0.88 1.61 
13 24.58 11.16 50.44 56.18 1.63 1.28 
14 26.23 33.75 6.41 11.91 1.91 1.96 
15 38.46 12.35 14.05 41.57 2.09 2.11 
16 39.18 7.68 21.21 22.85 1.60 3.83 
17 64.65 24.41 34.03 28.81 1.21 1.32 
18 24.32 17.02 5.72 9.54 0.67 0.75 
19 14.13 15.32 6.80 18.87 5.92 5.06 
20 22.88 45.63 6.19 10.14 - - 
21 22.12 17.28 5.99 5.72 - - 
22 329.16 188.84 4.29 3.81 - - 
23 101.73 109.91 7.44 14.46 - - 
24 37.48 18.21 7.64 11.05 - - 
25 1773.87 1195.64 6.25 7.74 - - 
26 1295.03 831.39 6.32 8.10 - - 
27 1766.85 1304.97 3.59 4.07 - - 
28 906.23 252.57 8.18 9.22 - - 
29 322.73 1521.29 19.49 4.50 - - 
30 114.01 1271.79 4.70 4.09 - - 
Measurements before and after treatment (– denotes missing values). 
 
Appendix 14 Raw salivary vitamin-binding protein concentrations for a 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Composition (per litre): 
D(+)-Glucose anhydrous 40 g 
Casein hydrolysate "Vitamin-free" 15 g 
L-Asparagine 200 mg 
L-Cysteinium chloride 200 mg 
L-Cystine 400 mg 
DL-Tryptophan 400 mg 
Adenine 20 mg 
Guanine 20 mg 
Uracil 20 mg 
Xanthine 20 mg 
4-Aminobenzoic acid 2 mg 
L(+)-Ascorbic acid 4 g 
D(+)-Biotin (vitamin H) 10 μg 
Calcium D(+)-pantothenate 1 mg 
Folic acid 200 μg 
Nicotinic acid 2 mg 
Pyridoxal hydrochloride 4 mg 
Pyridoxine hydrochloride 4 mg 
Pyridoxamine hydrochloride 800 μg 
Riboflavin 1 mg 
Thiaminium dichloride 1 mg 
Potassium phosphate dibasic 1 g 
Iron(II)sulfate 20 mg 
Potassium phosphate monobasic 1 g 
Magnesium sulfate 400 mg 
Manganese(II) sulfate 20 mg 
Sodium acetate anhydrous 20 g  
Sodium chloride 20 mg 
 
Appendix 16 Composition of vitamin B12-free microbial culture medium (6.3.7) 
